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Assessment of Carcinogenic Risk and the Delaney Clause:
The Search for a Better Standard
Mark A. Cleaves*
I.Introduction
The determination of whether a chemical agent is a carcinogen is often a
difficult task. Once carcinogenic potential is established, it is equally difficult
to regulate the compound so that the public-at-large is not exposed to haz-
ardous levels. When these agents are found in the food supply, the U.S.
Food and Drug Administration (FDA) has the responsibility for the determi-
nation of safety., Due to the complex nature of cancer and, at least until re-
cently, uncertainties of its mechanism, the determinations of when a com-
pound was safe under the Food, Drug and Cosmetic Act of 19382 and when it
was carcinogenic were mutually exclusive events. Recent scientific develop-
ments require that the regulation of carcinogens by the FDA be re-evaluated.
Cancer is the uncontrolled or malignant growth of somatic cells which of-
ten results in the death of an organism.3 As of 1978 it was the second largest
killer in the U.S. 4 A causal relation between this disease and death has been
established for centuries,5 but it has only been within the last few decades
that the prevalency and mechanism(s) of action have been elucidated. Tu-
mor growth may be initiated by a variety of agents; one of the more impor-
tant routes of exposure to these agents is via the ingestion of food.6 This con-
*B.S. Toxicology, Northeastern University 1983; M.S. Pharmacology/Toxicology Northeast-
ern University, 1987. J.D. Delaware Law School of Widener University, Wilmington, Delaware,
1987. The author would like to thank Dr. David R. Brown, Sc.D. and Rosann Reinhart for their
helpful commentary on this artide.
'Since 1906 federal law has forbidden adulterated and misbranded foods in interstate com-
merce. Federal Food and Drug Act of 1906, Pub. L. 59-384, 34 Stat. 768. (1906) (Repealed) The
Food and Drug Administration was formerly part of the U.S. Department of Agriculture and
was created to regulate food safety pursuant to the 1938 Food, Drug and Cosmetic Act, infra
note 11.
2Federal Food Drug and Cosmetic Act of 1938, Pub. L. No. 75-717, 52 Stat. 1040 (1938) (cur-
rent version at 21 U.S.C. § 321 (1970)); see also infra note 79 and accompanying text ("safe").
3See infra notes 202-216 and accompanying text (cancer process). Somatic cells are non-
reproductive cells of the body which make up all of the bone and soft tissues. DORLANYS POCKET
MEDICAL DICTIONARY 133 (23rd ed. 1982).
4The Reader's Digest 1987 Almanac 454 (1987) (14th Am. ed. 1983). Cancer as a cause of mor-
tality was second only to heart disease, its death rate 351.3 per 100,000 persons.
5Ramazzini in 1700 noted that nuns had a higher incident of breast cancer than other
women. Port also noted the occurrence of scrotal cancer in chimney sweeps in London, 1775.
See also Chemical Carcinogens: A Review of the Science and Its Associated Principles, 50 Fed.
Reg. 10,372 (1985) [hereinafter Principles]. See generally J. DOULL, C. KLASSEN, and M. AMDUR, CA-
SARETr&DoULL's ToxOCOLOGY Ch. 6 (2d ed. 1980). [Hereinafter CASARErT & DOULL].
6See Principles supra note 5, at 10,383-10,387 (carcinogens may be of chemical, viral, physical
or radiational origin, all of which may induce cancer and maybe found in food).
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cern has lead Congress to adopt the strict standards found in the Food, Drug
and Cosmetic Act,' which are meant to keep carcinogens out of the nation's
food supply. These standards are found in three amendments dealing with
food additives,8 color additives9 and drugs which are to be used in feed ani-
mals. 10 Each of these contain an anti-cancer provision known as the Delaney
Clause," named after the Chairman of the House Select Committee to Inves-
tigate the Use of Chemicals in Foods (1950-1953).12 This legislation was
passed due to the great public concern that foods and their contaminants
were responsible for the deterioration of the nation's health. 13
This article will focus upon the legislative history and subsequent case
law dealing with the Delaney Clause and it will include the rationale and
limitations of the provision. In order to regulate carcinogens one must have
a clear understanding of the cancer processes. Therefore a brief discussion of
the biological parameters involved is warranted. The purpose of this discus-
sion is to find a more rational alternative to the Delaney Clause. The use of
quantitative risk assessment as an approach to regulate carcinogens found
in food is also discussed. By combining the purposes of the original (and cur-
rent) statutory provisions with current technologies, a more efficient and
workable regulation of carcinogens may be effectuated.
The Delaney Clause was enacted as a result of legitimate societal concerns
and, while technologically faulty, '4 the amendment should not carelessly be
dismissed. The original legislative intent may be better appreciated by tak-
7Supra note 2
'Food Additive Amendments of 1958, Pub. L. No. 85-929 § 4, 72 Stat. 1784, 1786 (1958) (ad-
ding § 409(c)(3)(a) of the Act) (current version at 21 U.S.C. § 341 (1970)).
9Color Additive Amendments of 1960, Pub L. No. 86-618, 74 Stat. 397 (1960) (adding §
706(b)(5)(B) of the Act) (current version at 21 U.S.C. § 376 (1970)).
10Animal Drug Amendments of 1968, Pub. L. No. 90-399, 82 Stat. 342 (1968) (adding §
512(d)(1)(H) of the Act) (current version at 21 U.S.C. § 360b (1970)).
"The "Delaney Clause" refers to specific portions of §§ 409, 706, and 512 of the Food, Drug
and Cosmetic Act (FD&C Act), Pub. L. No. 75-717, 57 Stat. 1040 (1938) (Amended 1980). It de-
rives its name from Congressman Delaney (D-N.Y.) who chaired the House Select Committee
to Investigate the Use of Chemicals in Foods which was responsible for the enactment of the
Clause. [Hereinafter Delaney unless otherwise specified] Infra note 46 and accompanying text
(Delaney Clause text as amended in 1964).
"Hearings on H.R. 74 Before the House Select Committee to Investigate the Use of Chemicals in Food
Products, 81st Cong., 2d Sess. (1951). These hearings were also the origin of the Pesticide Chem-
ical Residue Amendments of 1954, Pub. L. No. 518, 68 Stat. 511 (1954) (current version at 21
U.S.C. § 346a (1970)).
13See Matson, Scientific Judgement in Law and Regulation, 15 FOOD DRUG CoSM. L.J. 70, 74-75
(1960) (providing excerpts from House proceedings in 1959).
"See infra note 192 and accompanying text (scientific flaws of the Delaney Amendment).
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ing into account current technologies in toxicology and other related fields.
One such methodology, Quantitative risk assessment allows for the estab-
lishment of "Virtually Safe Doses" (VSD), 5 which are based on statistical
evaluation of cancer processes. Although these procedures represent a new
approach to the determination of safe levels of carcinogens, an evaluation of
these approaches as they relate to scientific judgment and priority setting is
required. 16 Quantitative risk assessment overcomes the scientific shortfalls
of Delaney while protecting the American public from hazardous levels of
carcinogenic substances.17
II.Legislative History and Judicial Interpretation of the Delaney Clause
Since the beginning of this century the American public has been acutely
aware of the hazards of contaminated food.8 It was therefore no surprise
that in 1906 the newly enacted Federal Food and Drug Act 9 contained a pro-
vision that made a food adulterated, and thus illegal, if it contained any poi-
sonous or deleterious substance which rendered it injurious to health. This
same provision is currently embodied in Section 402(a)(1) of the 1938 Federal
Food, Drug and Cosmetics Act (FFDCA). 0
""Virtually Safe Dose" has been defined as the dose corresponding to a suitably low level of
risk and is defined in terms of an increase in tumors over the spontaneous background rate that
is within an acceptable limit. Crump, Guess and Deal, Confidence Intervals and Tests of Hypotheses
Concerning Dose Response Relations Inferred from Animal Carcinogenicity Data, 33 BIOMETRICs 437
(1977). See also text accompanying note 258.
"See infra note 228 and accompanying text (scientific judgment and risk assessment instead
of an established zero tolerance).
"
7 See infra note 29 and accompanying text (the original purpose of Delaney was to protect the
American public from carcinogens in food). But see note 198 and accompanying text (impossibil-
ity of banning all carcinogens).
"Most of this awareness was brought about by Dr. Harvey Wiley who mobilized the famous
"poison squad", which exposed young volunteers to food containing chemicals to observe ad-
verse effects. See CAsARErr & DOULL, supra note 5, at 593. As a result of this concern the doctrine
of strict liability in tort began to emerge to provide a remedy for aggrieved parties that had suf-
fered damages due to adulterated foods. See PROSSER AND KEETON ON THE LAW OF TORTS, 690 (5th
ed. 1985).
"See supra note 1 (1906 Act).
2021 U.S.C. § 342 (1938) (as amended 1970). There are numerous sources of the general legis-
lative history of the FFDCA. See generally, Regier, The Struggle for Federal Food and Drug Legisla-
tion, 1 LAW & CONTEMP. PROBS. 3 (1933); U.S. GOV'T. PRINTING OFFICE, A BRIEF LEGISLATIVE HISTORY
OFTHE FOOD, DRUG AND COSMETIC Acr.
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This Act, which expanded the 1906 Act, contained provisions to regulate
naturally occurring, necessary and unavoidable constituents of foodstuffs. 21
These categories were set forth to distinguish between constituents that
were "added" and those which were not." It was unfortunate, however,
that neither the 1906 nor the 1938 Act defined what "added" actually
meant. 3
As food technology advanced and awareness of the potential dangers of
food additives grew, post-WWII America realized that more substantive
regulation was required. By the early 1950's, not only had the detection of
food contaminants become more feasible, but also the use of food additives,
and chemical pesticides had increased. 24 In September, 1950, the House Se-
lect Committee to Investigate the Use of Chemicals in Foods held hearings,
in which witness after witness testified to the horrors of the past years in-
cluding the Elixir of Sulfanilamide and the "Ginger Jake" paralysis trage-
dies.n From the beginning it was clear that a new food-additives regulation
was in the offing, but the hearings, nicknamed the "Delaney" Hearings after
their Chairman, continued for the next two years. 6
In 1958, after much debate, Section 409 was added to the FFDCA. It es-
tablished a premarket approval scheme containing a general safety clause
2"Provisions covering natural food constituents and unavoidable added constitutents are
contained in Food, Drug and Cosmetic Act H 402(a)(1), 406; 21 U.S.C. §§ 342, 346 (1938) (as
amended 1970).
"ld.. See U.S. v. Lexington Mill & Elevator Co., 232 U.S. 399 (1914). Section 402(a)(1) pro-
hibits poisonous or deleterious substances which make food injurious to health. The Supreme
Court found this to mean a reasonable certainty of no harm under the actual conditions of use.
'See Kopka, "If Mother Only Knew": Regulating Carcinogens in Food Additives, 31 MED. TRIAL
TECH. Q. 273, 275 (1983). [Hereinafter Regulating Food].
'An example of the exportential growth in these chemicals from WWII to 1973 is exemplified
by the growth of pesticides (680%) and flavors (400%). See NATIONAL SCIENCE FOUNDATION,
CHEMICALS AND HEALTH (1973). See generally A. GOLDSTEIN, L. ARONOW AND S. KALMAN, PRINC-
PLES OF DRUG AcTION 359-74 (2d ed. 1974) [hereinafter PRINCIPLES OF DRUG ACTION]. The first act
concerning chemical regulation was the Pesticide Chemical Residue Amendments of 1954, see
supra note 12.
2 Supra note 14 (Delaney Hearings). In 1937, 105 out of 353 people died from ingesting sul-
fanilamide suspended in diethylene glycol, which was manufactured and sold by S. E. Mas-
sengill Co. Inadequate tests as to the toxicity of the solvent were to blame. See R. MERRILL AND P.
Hurr, FooD AND DRUG LAW 369 (1980); CASARErr & DoULL, supra note 5, at 483. In 1930 ginger
extract adulterated with tri-orthocresyl phosphate was added as a flavoring agent to bootleg
whiskey. Those who ingested it suffered progressive paralysis of the limbs. See CASARETr &
DOULL, supra note 5, at 368.
'Congressman Delaney chaired the proceedings from 1950-1953. See generally Klienfeld, The
Delaney Proviso - Its History and Prospects, 28 FOOD DRUG COSM. L.J. 556 (1973) (containing ex-
cerpts from the hearings). [Hereinafter Delaney Proviso].
"21 U.S.C. § 348 (as amended 1970), supra notes 8 and 11 with accompanying text (1958 Food
Additive Amendments).
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which requires that a food additive be found "safe" for its intended use.2 8
This amendment was intended to mirror the national concern as to the pres-
ence of chemicals in food and it was designed to prevent all diseases and
disabilities arising from food additives.
The Amendment, however, went much further. The final portion of Sec-
tion 409 contained a clause that attempted to outlaw cancer at its source. 2'
Representative Delaney was convinced by the testimony of the witnesses at
the hearings that all carcinogens in food must be banned. Compounding De-
laney's fears, was an unfortunate coincidence. The wife of one of his close
aides had contracted cancer during the proceedings. Delaney felt that the
need for an anti-cancer clause was exigent, and began to search for the
proper provision. 10
The origin of the Delaney Clause may be traced back to 1954. In Rome the
International Union Against Cancer, gathered and drew important distinc-
tions between reversible and irreversible chemical processes." Scientists de-
termined that threshold limits could be set for those chemicals which react
reversibly in biological systems but that small doses of irreversibly-acting
chemicals must be considered dangerous.3 Two years later this concept was
codified in an International Conference Against Cancer recommendation for
proposed rules on food additives; the substance of the recommendation was
seized upon by Chairman Delaney.33
The Union's findings, which considered even low doses dangerous, pre-
cluded the setting of any tolerances for these chemicals. This view was not
espoused by all. In fact the FDA was not originally in favor of the clause.
Perhaps it realized the scientific limitations of the concept or could foresee
the problems of banning all food additives that cause cancer.
21 U.S.C. §321(s).(1970) See infra text accompanying note 45 (definition of "food additive").
2' Under § 409 a food additive would be deemed unsafe if based on relevant data the propo-
nent fails to set forth conditions for its use. Safety is satisfied by meeting 201(s). Section 409
contains a specific anti-cancer clause, even though a finding of carcinogenicity would render
the substance unsafe. 21 U.S.C. § 348(c)(3)(A) (as amended 1970).
2' See Delaney Proviso, supra note 26, at 559.
"See Wade, Delaney Anti-Cancer Clause: Scientists Debate on an Article of Faith, 177 SCIENCE 588,
589 (1972). [Hereinafter Article of Faith].
"At the time the concept of irreversible one-hit effects of carcinogens was the only viable
theory. Recent studies have since shown this to be not entirely true. See infra notes 202-249 (ge-
netic vs. epigenetic carcinogens) and 211 (DNA Repair Mechanisms).
3In 1956 the International Conference Against Cancer recommended that "as a basis for ac-
tive cancer prevention, the proper authorites of various countries promulgate and enact ade-
quate rules and regulations prohibiting the addition to food of any substance having potential
carcinogenicity." See Article of Faith, supra note 31, at 589.
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The FDA noted that the first portion of the food additives amendment,
known as the "General Safety Clause," and the second portion, the "Dela-
ney Clause," were redundant. It reasoned that if a chemical were found to
be carcinogenic it could never be considered safe, and thus would be denied
market approval.3 This argument is flawed, however, because the General
Safety Clause allows a risk-benefit analysis to set tolerances, while the Dela-
ney Clause does not.- Nevertheless, the 1958 Food Additives Amendment
was passed.3 7
Pursuant to Section 402(A)(1) of the 1938 Act, if a food contains "any poi-
sonous or deleterious substance injurious to health" it is deemed adultera-
ted and held illegal." Under Section 402(A)(2)(a),1 deleterious substances
are pesticides, food additives, color additives' and new animal drugs.4
Prior to 1958, these sections required the agency to show that the levels of
these substances found in food were not safe." Section 4 0 94 of the 1958
Amendment specifically covers food additives. Food additives are defined
by Section 201(s) of the Act as
[a]ny substance the intended use of which results or may reasonably
be expected to result, directly or indirectly, in its becoming a compo-
nent or otherwise affecting the characteristics of any food (including
-'Section 409(c)(1)(A) of the Act sets out conditions for safe use of food additives. The FDA's
position that the Delaney Clause would be redundant in light of the general safety clause is
found in a letter written by then Assistant Secretary Elliot Richardson to the Delaney Commit-
tee. See Allera, An Overview of How the FDA Regulates Carcinogens Under the Federal Food, Drug and
Cosmetic Act, 33 FOOD DRUG COSM. L.J. 59 (1978) [Hereinafter Overview]; FDA Answers to Ques-
tions Submitted at Conference Cosponsored by FDA and FLat Washington on November 16-17, 1959, 15
FOOD DRUG COSM. L.J. 213 at 214 (1960) (In referring to Senate Report No. 2422, 85th Cong., 2d
Sess. (1958), the FDA affirmed that its position was that "the bill reads and means the same with
or without the inclusion of the (Delaney) Clause...").
31A finding that a substance was carcinogenic would in most cases, cause for it to be barred
under the risk-benefit analysis of § 406 of the Act. Under § 409 with the Delaney Clause the risks
automatically outweigh the benefits as a matter of law. Accord Regulating Food, supra note 23, at
277.
1Id. See 21 U.S.C. § 348(c)(4) (1970) (allows for setting of tolerances).
37Supra note 8.
m21 U.S.C. § 342 (as amended 1970) (adulterated food).
"Id.. (enumeration of specific adulterants).
'Regulation of pesticides is covered under § 408 of the Act, the FDA, however, defers to
U.S.D.A.'s setting and measuring of levels. 21 U.S.C. § 346a (as amended 1970).
"See infra notes 77-80 and accompanying text. (regulation of color additives).
'See infra notes 81-94 and accompanying text. (regulation of new animal drugs).
"The 1938 Act required that the FDA show that an intentionally added food substance was
injurious to health. 21 U.S.C. § 342 (1938).
421 U.S.C. § 348 (as amended 1970) (Food Additive Amendment of 1958).
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any substance intended for use in producing, manufacturing, pack-
ing, processing, preparing, treating, packaging, transporting, or
holding food; and including any source of radiation intended for
any such use), if such substance is not generally recognized, among
experts qualified by scientific training and experience to evaluate its
safety, as having been adequately shown through scientific proce-
dures (or, in the case of a substance used in food prior to January 1,
1958, through either scientific procedures or experience based on
common use in food) to be same under the conditions of its intended
uses l
The Delaney Clause, Section 409(C)(3)(a) reads
... Provided, that no additive shall be deemed to be safe if it is
found to induce cancer when ingested by man or animal, or if it is
found, after tests which are appropriate for the evaluation of the
safety of food additives, to induce cancer in man or animal ....
The Amendment is a pre-market screening device for food. It is specifi-
cally designed to prevent the addition of any substance that has been shown
to induce cancer in man or laboratory animals. The practical effect of this
amendment, however, is to shift the burden of testing the additive and
proving its safety to the proponent of its use.45 More importantly, the
Amendment had the effect of precluding the setting of safe tolerances for the
amount of an additive deemed unsafe if it caused cancer.49 The only issue left
is to decide whether the additive did in fact cause cancer. This is accom-
plished after "a fair evaluation of the data before the Secretary". °
The scope of the Delaney Clause is limited by two exceptions to coverage.
The first exception covers substances "generally recognized as safe" (GRAS)
121 U.S.C. 321(s) (1964).
4621 U.S.C. § 348 (as amended 1970).
4Id. Accord R. MERRILL AND P. HuTrn, FOOD AND DRUG LAW 77 (1980). But see infra note 91 (New
Animal Drug Amendments of 1962 and 1968 do allow such additions pursuant to specific condi-
tions).
41See Chemical Compounds in Food Producing Animals: FDA Proposed Criteria and Proce-
dures for Evaluating Assays for Carcinogenic Residues, 44 Fed. Reg. 17,070 (1979). [Hereinafter
Evaluating Assays.]
111d. This has been interpreted by some as the setting of a zero tolerance. Martin, The Delaney
Clause and Zero Risk Tolerance, 34 FOOD DRUC CoSM L.J. 43 (1979) (Congressman Martin, then
member of the Health Subcommittee of the House Ways and Means Committee, objected to the
setting of such tolerances because many naturally occurring substances were in fact carcino-
gens).
21 U.S.C. § 348(c)(3)(A) (1970).
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by experts.5 1 The second pertains to those substances that were sanctioned
prior to 1958 by the FDA or U.S. Department of Agriculture (USDA), i.e.
"prior sanctioned substances."u
The text of these exceptions appears to be straightforward, but in practice
it is not. Substances generally recognized as safe include ingredients that
have enjoyed a long history of use, such as salt, pepper, sugar, etc. m A GRAS
classification may have been granted prior to 1958 or even after if the rele-
vant data evaluated by the experts, proved the substance to be safe. If, how-
ever, new data shows that the ingredient is in fact a carcinogen then it will be
taken off of the list. s' Carcinogenicity precludes an expert from finding the
ingredient safe; once this occurs the substance is deemed to be a food addi-
tive and is subject to Delaney prohibition. m Such is the case with Saccharin.
The FDA's "Grandfather Clause" of prior sanctioned substances precludes
the use of Delaney, however, and new data that questions an ingredient's
safety is evaluated according to Section 402(a)(1).51
It should also be noted that Delaney coverage does not extend to natural
food constituents such as vitamins, minerals and animal biochemicals. m The
FDA, has also held that unavoidable added food constituents are not subject
to the Delaney Clause.M The FDA bases this determination on two assump-
5121 U.S.C. § 321(s) (1970). The definition of "food additive" exempts substances generally
recognized as safe by experts for their intended uses, as shown through scientific procedures.
5221 U.S.C. § 321(s)(4) (1970) (Prior sanctioned substances).
13General food categories are codified in 21 C.F.R. § 170.3(n) (1985); criteria for determining
GRAS are found in 21 C.F.R. § 121.400 (1985).
5FDA periodically reevaluates data as to a substance's safety 21 C.F.R.§ 170.35 (1985). If the
data raises a substantial question as to safety but most of the scientific evidence favors safe use,
the FDA may issue an interim food additive regulation until all the data is supplied. 21 C.F.R. §
180.1 (1985).There has been much scientific controversy surrounding the term "safe" as found
in the GRAS provision. See Turner, The Delaney Anticancer Clause: A Model Environmental Protec-
tion Law, 24 VAND. L. REV. 889, 895-898 (1971). [Hereinafter Protection Law].
5Supra note 35 and accompanying text. Application for approval of use would then be with-
drawn. See Cyclamate, Commissioner's Decision 45 Fed. Reg. 61,174 (1980) (Cyclamate salts
withdrawn from GRAS list); infra note 218 and accompanying text.
16Infra notes 221-223 and accompanying text.
5121 C.F.R.§§ 181.1, 181.5 prior sanctioned ingredients are exempt from classifications as
food additives, but not from other adulterations standards under § 402(a)(1)); Accord Overview,
supra note 34, at 75.
5 Supra note 21 and accompanying text. Under Section 701(a) of the Act, FDA under its au-
thority to promulgate regulations for efficient enforcement could ban a natural constituent. 21
U.S.C. § 371 (1970). See 21 C.F.R. § 189.180(b) (1985); 41 Fed. Reg. 19,207 (1976) (FDA ban of
sassafras tea because safrole was found to be carcinogenic). But see U.S. v. Article of Food...
Seelect Natural Herb Tea, C.A. No. 73-1370 (C.D. Cal. 1978) (manufacturer voluntarily with-
drew claim after judge denied summary judgment).
5921 C.F.R.§ 109 (1985).
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tions. Although a substance may be "added" as within the meaning of Sec-
tion 402(a)(1),60 for Section 409 to attach, the compound must be functional
upon addition to food; if the ingredient has no functional purpose, then Sec-
tion 409 and Delaney do not apply.61 Secondly, the FDA does not believe that
the legislative intent was present for the food additives amendment to cover
substances of this sort. 2 Like naturally occurring constituents, these sub-
stances are subject to Section 402(a)(1) treatment, but once "added" they
may render the food "adulterated" and consequently are subject to Section
406 tolerance setting.6 This section sets forth two criteria used to determine
adulteration tolerances for poisonous compounds: 1) levels that will not
pose a significant risk to public health and, 2) the extent to which contamina-
tion cannot be avoided by good manufacturing practices." Implied by this
section is the requirement that the FDA be able to measure the constituent;
obviously the FDA cannot set a tolerance level that is beyond its ability to
detect."
It is clear that the food additive provision in the Delaney Clause was
meant to circumvent the uncertainties present concerning carcinogens. The
main thrust of this legislation was designed to insure that food was generally
safe as well as free from carcinogens.' Two years after Congress passed the
Food Additive Amendment the Delaney Committee proposed the Food
Color Additive Amendment. 17
By 1960, the controversy surrounding the Delaney Clause in the 1958
Amendment had had time to ferment. Disputes arose not only between poli-
6021 U.S.C. § 342 (a)(1) (1970) (if a poisonous substance is not an "added" substance, then a
food is not considered adulterated under the clause.)
6121 U.S.C. § 348(c)(4)(B) (1970) (Provision allows no regulation if "data do not establish that
such use would accomplish the intended physical or other technical effect"); 21 C.F.R. 170.30
(1985).
625. Rep. No. 2422, 85th Cong. 2d. Sess., reprinted in 1950 U.S. CODE CONG. AND ADMIN. NEWS
5300 (Food Additives Amendments of 1958. Functional requirement for additive to be ap-
proved).
6
-This mechanism avoids Delaney. Even though the substance is considered added and is
found to be carcinogenic it is regulated by the risk-benefit analysis of § 406 of the Act rather than
§ 409. See 21 U.S.C. § 342(a)(2)(A) (1970) (food is adulterated if found unsafe under § 406). But see
supra note 55 and accompanying text. (Thus it would seem that all carcinogenic substances are
not always found unsafe.)
"21 U.S.C. § 346 (1970).
6Infra note 170 and accompanying text (Sensitivity of method to detect low levels of haz-
ardous substances).
6"Accord Protection Law, supra note 54, at 902.
67Supra note 9. (Color Amendments of 1960).
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ticians and scientists, but also among scientists.6 The National Academy of
Science (NAS) was anti-Delaney whereas the National Cancer Institute
(NCI) was firmly pro-Delaney. 6This conflict was fueled by conflicting re-
ports by both groups.n The NCI voiced legitimate concerns as to the uncer-
tainties of setting tolerances for known carcinogens.,' Extensive evaluation
of data and current theories of carcinogenesis lead to a NAS Food Protection
Committee report on food additives which concluded that per se regulation
of carcinogens was inappropriate, n Despite the fact that this report was thor-
ough and scientifically valid (and still considered so today) allegations of
bias, weighed heavily against the report.7 Throughout the hearings, these
conflicts continued and did little to promote rational decision-making. 74
Because of the uncertainties in the cancer process and the persisting soci-
etal fear of the disease, the Food Color Amendment contained a Delaney
Clause.7h The Amendment as enacted is basically the same as the 1958
Amendment, in that the proponent of the additive still had to prove its non-
carcinogenic character. 76 To make such determinations the Amendment em-
ploys an ad hoc scientific advisory committee.1 The purpose of the commit-
tee, convened by the Secretary or an adversely affected party, is to resolve
Delaney questions. It does not mitigate Delaney prohibition of a color addi-
tive, but supplements data to aid in the Secretary's determination.' There is
no GRAS listing however. Instead, a "provisional listing" of the additive is
"See generally Hutt, Public Policy Issues in Regulating Carcinogens in Food, 33 FOOD DRUG COSM.
L.J. 541 (1978); Articleof Faith, supra note 31, at 589 (citing excerpts from hearings and discussion
of NCINAS conflict).
69Article of Faith, supra note 31, at 589.
71d.
"H.R. Rep. No. 1761, 86th Cong. 2d Sess., reprinted in 1960 U.S. CODE CONG. AND ADMIN.
NEws 2887 (Color Additive Amendments of 1960- role of certain chemical and physical agents in
the causation of cancer).
"Subcomrnittee on Carcinogenesis, Food Protection Committe, Food and Nutrition Board,
NAS-NRC, Problems in the Evaluation of Carcinogenic Hazard from Use of Food Additives 21 CANCER
RES. 429 (1961).
"See Article of Faith, supra note 31, at 589.
Al"d.
"See infra note 86 (color additives amendement for public protection but carcinogenic addi-
tives should be allowed where residues do not occur in the edible portions of animal products).
1621 U.S.C. § 378(b)(5)(B) (1970) (Anti-cancer Clause).
"21 U.S.C. § 376(b)(5)(c)(i) (1970) (allows for advisory committee review of data upon peti-
tion from Secretary or petitioner). This advisory committee is limited to review only as to the
cancer issue and not free to deal with "any question of fact". See H.R. Rep. No. 6747, 85th Cong.
1st Sess. (1957) (similar restrictions are placed on the committee sanctioned by Pesticide
Amendment of 1954).
781d.
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allowed to the extent consistent with public health until such time that deter-
minations can be made as to its safety. I Thus, colors provisionally listed are
technically outside of the Delaney Clause. 10
During the hearings for the Food Colors Additive Amendment the Secre-
tary of the Department of Health, Education and Welfare (HEW) expressed
concern over the scope of the anti-cancer clause and wanted it modified to
cover additives to animal feeds and animal drugs."1 Although unsuccessful
in 1960, this concern remained. The livestock industry was distraught be-
cause following the 1958 Food Additive Amendment, the FDA allowed the
use of diethylstilbestrol (DES) in sheep and cattle but denied approval for
new uses of the drug. 2 Section 201(u), which defines "safe", expressly
covers the health of both man and animal. Within the purview of Delaney,
Congress recognized the potential adverse effects on humans from animal
drug residues in animal products.4
In 1962 the Delaney Clause was added to a bill regarding FDA regulation
and approval of new animal drugs." The Senate passed over the provision
without changes, but the House Committee on Interstate and Foreign Com-
merce made technical modifications that clarified its purpose and scope."
Included were clauses that allow for use of the additive it if did not adversely
affect the animal and if no drug residues were found (by methods prescribed
by the Secretary) on any edible product of the animal.87 This clause became
1d.
a'Color Additive Amendments of 1960, Pub. L. No. 86-618, § 203, tit. II, 74 Stat. 397; (1960).
(Mandating provisional listings of commercially established colors).
"See Evaluating Assays supra note 48, at 17,072.
2Dieythlstilbestrol is an anabolic steroid used primarily to promote growth and fatten live-
stock. It was first approved for use in premixed animal feeds in 1954 and later as a sustained-
release implant in 1955. Due to the 1958 Food Additive Amendments, no new animal drug ap-
plications were approved by the FDA. See S. Rep. U.S. 1744, 87 Cong. 2d Sess., reprinted in 1962
U.S. CODE CONG. AND ADMN. NEws 2884 (Drug Amendments of 1962).
321 U.S.C. § 321(u) (1970) ("the term 'Safe' ... has reference to the health of man or ani-
mal").
"See Evaluating Assays, supra note 48, at 17,072. In passing §§ 409 and 706 of the Act Con-
gress sought to recognize that animal drug residues would end up in man's food supply. FDA
interpreted these provisions as forbidding it from approving the use of animal drugs thought to
be carcinogenic.
'Drug Amendments of 1962, Pub. L. No. 87-781, 76 Stat. 780, 21 U.S.C. § 360b(d)(1)(H)
(1962).
'Supra note 71 and accompanying text (these modifications allowed DES to be used in the
livestock industry).
'Official Methods for Detection, Identification and Measurement of DES Residues, 28 Fed.
Reg. 1,507 (1963). These were changed several times, current criteria are found in Evaluating
Assays, supra note 48. Revised threshold assessment guidelines are found in 47 Fed. Reg. 4,973
(1982).
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known as the DES Proviso., Pro- and anti-Delaney forces seized upon the
opportunity to exchange views as to the proper method of regulating carcin-
ogenic substances. 
I
Due to unprecedented growth in the animal feed and drug industries,9
there was a move to consolidate the FFDCA provisions regulating the pre-
marketing approval of animal drugs and feed additives.9 In 1968 the Animal
Drug Amendments under Section 512(d)(1)(H) were passed.w This amend-
ment also contained an anti-cancer clause with "DES Proviso" attached:
(H) such drug induces cancer when ingested by man or animal or,
after tests which are appropriate for the evaluation of the safety of
such drug, induces cancer in man or animal, except that the follow-
ing provisions of this subparagraph shall not apply with respect to
such drug if the Secretary finds that, under the conditions of use
specified in proposed labeling and reasonably certain to be followed
in practice (i) such drug will not adversely affect the animals for
which it is intended, and (ii) no residue of such drug will be found
(by methods of examination and prescribed or approved by the Sec-
retary by regulations, which regulations shall not be subject to sub-
sections (c), (d), and (h)), in any edible portion of such animals after
slaughter or in any food yielded by or derived from the living ani-
mals .. .
This clause followed the Congressional intent of the 1962 New Animal
Drug Amendment and continued to allow the FDA to vigorously regulate
new animal drugs.9'
8See 108 CONG. Rc. 19,916-19,920 (1962).
O'Representative Leonor K. Sullivan (D-MO) protested that this proviso would "weaken in-
stead of strengthen consumer protection". Senator H. Humphrey (D-MN) noted that the full
vigor of the Delaney Clause had been preserved.
"See Chemicals and Health, National Science Foundation (1973) (listing over 40 common
animal drugs and feed additives).
"In 1968 Congress consolidated §§ 409, 505, and 507 which dealt with premarketing ap-
proval of drugs. Consequently the animal drug amendments were added under 512(d)(1)(H) of
the Act. 21 U.S.C. § 360b(d)(1)(H) (1968).
921d.
93d.
"'See S. Rep. No. 1308, 90th Cong. 2d Sess., reprinted in 1968 U.S. CODE CONG. AND ADMIN.
NEWS 2607 (annual Drug Amendments of 1986. Delaney anticancer prohibition and the FDA
authority to be maintained).
[Vol. 2:173
1987-88] THE DELANEY CLAUSE
It must be preliminarily noted that the Delaney Amendment is seldom
used to ban the food ingredients which it is meant to regulate.5 This is be-
cause a positive indication of cancer induction must be found in order for
Delaney to attach." While this is not impossible, the FDA has typically per-
formed safety evaluations according to the General Safety Clause of Section
409.97 Since its enactment, FDA has used the Amendment only in three in-
stances."
From 1969-1983 Congress said little about the regulation of carcinogens in
food and let the FDA, via its rulemaking powers, implement regulations.9
During this time, however, the judiciary kept busy with litigation arising
from these regulations. By far, most of the controversy surrounds the use of
diethylstilbestrol in feed animals."'
Before examining case law, however, it would be useful to review FDA
interpretation of Section 512(d)(1)(H) which deals with additives given to
animals.' This provision is capable of multiple interpretations."' Those in
"Prior to the 1958 Food Additive Amendments FDA had already removed food ingredients
suspected to be carcinogenic. In 1950 the artifical sweetners Dulcin and P-4000 were banned. 15
Fed. Reg. 321 (1950). In 1954 the use of the drug Coumarin in food was banned. 19 Fed. Reg.
1,239 (1954). After enactment'of the anticancer clause it has been rarely used. It has been used in
1967 and 1969 to ban cyclamates 32 Fed. Reg 5,675 (1967), 34 Fed. Reg. 17,063 (1969): and in 1977
to ban Saccharin, 42 Fed. Reg. 19,996 (1977). Instead FDA has opted to use the general safety
clause to ban carcinogens, e.g. 25 Fed. Reg. 12,412 (1960) (Safrole); Bell v. Goddard, 366 F.2d 177
(7th Cir. 1966) (DES in Caponette poultry); 43 Fed. Reg. 17,063 (1969) (Cyclamates); Certified
Color Mfgs. v. Matthews, 593 F.2d 284 (D.C. Cir. 1977) (Red Dye No. 2).
%in all anticancer provisions the substance must be shown to induce cancer in man or ani-
mals, these provisions allow no room for suspicion. Because the general safety clause employs a
risk-benefit test a substance's carcinogenic potential is also a factor. See 21 U.S.C. §§ 348(c)(3)(A)
(1970), 376(b)(5)(B) (1960) and 360b(d)(1)(H) (1968) (Anticancer Clauses); 21 U.S.C. § 346 (1970)
(use of risk-benefit test in setting tolerances pursuant to 402(a)).
97See supra note 11.
"See generally supra note 95.
"21 U.S.C. § 371 (1976) (General Administration Provisions - regulations, rulemaking and
hearings).
1
"See Bell v. Goddard, 366 F.2d 177 (7th Cir. 1966) (use of DES in Caponette poultry); Hess &
Clark, Division of Rhodia, Inc. v. FDA, 495 F.2d 975 (D.C. Cir. 1974) (DES implants); Cheme-
tron Corporation v. U.S. Dept. of Health, Education and Welfare, 495 F.2d 995 (D.C. Cir. 1974)
(use of DES in livestock feed mixes); Animal Health Institute v. FDA, 11978 Transfer Binder]
Food Drug Cosm. L. Rep. (CCH) 38,154 at 38,557 (D.D.C. Feb. 8, 1978) (adequacy of notice
and comment rulemaking regarding DES detection methods); Rhone-Poulenc, Inc., Hess &
Clark Div. v. FDA, 636 F.2d 750 (D.C. Cir. 1980) (substantial evidence showing that DES was
unsafe).
'
t Supra notes 91-93 and accompanying text (text of § 512(d)(1)(H)).
"02See Evaluating Assays, supra note 48, at 17,073; infra text accompanying note 167 (discus-
sion of reproposal of SOM Regulations).
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favor of more progressive interpretation would like to believe that the FDA
would have to absolutely prove the presence of trace residues before ban-
ning the product.0 3 This interpretation is flawed in many respects especially
since it appears contrary to congressional intent. Scientifically, such proof is
impossible, because in most instances there would be traces of the chemical
residue no matter how minute in the animal. Such residues were beyond the
detection of FDA's analytical methods until only recently.°'4
Furthermore, it is contrary to congressional intent to interpret the provi-
sion in that manner. When Congress enacted the provision it used the word
"found" instead of "occur" or "remain", this evidenced reliance on detecta-
bility and not absolute presence. The term "no residue" is given the mean-
ing no detectable residue. 0 Congress also limited the provision to "condi-
tion of use", thus allowing compounds to remain on the market even if
residues were found, but not from intentional addition. 117 The more proba-
ble interpretation of the provision is that if a carcinogenic compound used in
animals is not detected by FDA in assays prescribed, the compound is free
from Delaney coverage.18
The first litigation to involve the DES Proviso was Bell v. Goddard. 09 In Bell,
a manufacturer of DES implants for the Caponette poultry industry contended
that FDA suspension of his New Annual Drug Application (NADA) was im-
proper. At the time the carcinogenic affect of DES was not completely
"'A literal reading could show § 512 to read "... if the Secretary finds that... no residue of
such drug will be found." See U.S.C. § 360b(d)(1)(H) (1970).
"S'upra note 102 and accompanying text (discussion of latest SOM detection limits).
laSee 21 U.S.C. § 360b(d)(1)(H) (1970) (text); Evaluating Assays, supra note 48, at 17,073.
(Noting statutory construction).
06id.
"See 21 U.S.C. § 360b(d)(1)(H) (1970) (text). Once a chemical is deposited in the environ-
ment it remains there until picked up by another organism. Thus environmental contaminants
such as DDT and even DES that were once used so pesticides or animal drugs may show up as
trace chemicals even though never intentionally given to the animals. See generally CASAREr &
DOULL, supra note 5, at 601.
This conclusion was expressed by Senator Kefauver during the new Drug Amendment
Hearings in 1962:
The provision stipulates that the anti-cancer proviso of existing law shall not apply with
respect to the use of a substance - for example, a veterinary drug - as an ingredient of
feed for animals which are raised for food production if the Secretary finds ... that no
residue of the additive will be found after slaughter or in any food product of the living
animal - such as milk or eggs. 108 Cong. Rec. 20,869 (1962).
Saee Hess & Clark, Div. of Rhodia, Inc. v. FDA, 495 F.2d 975, 980 (D.C. Cir. 1974); Cheme-
tron Corporation v. Dep't of Health Educ. and Welfare), 495 F.2d 995, 999 (D.C. Cir. 1974).
19366 F.2d 177 (7th Cir. 1966).
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known.110 The manufacturer contended that the FDA knew about DES' pro-
pensity to cause cancer, but it delayed a finding that DES was safe as used to
employ the Delaney Clause retroactively.' The court found that the FDA
had shown that DES was unsafe, and could wait until all the data was in.11
The FDA chose to ban DES based on its unsafe nature as prescribed by Sec-
tion 505(e) which pertains to new drugs."' Bell illustrates two points con-
cerning the FDA's regulation of drugs and additives. First, the FDA has
broad discretion as to what provisions to utilize in setting tolerances or ban-
ning such compounds.' 4 Second, it shows that no matter how safe the sub-
stance may be in relative terms of use, a finding of carcinogenic potential
may render it unsafe."5
The "DES" Proviso was again scrutinized in 1974 in Hess & Clark, Inc. Divi-
sion of Rhodia v. FDA." 6 The FDA had once again withdrawn the manufac-
turer's NADA for DES implants. The court recognized that the DES Proviso
carved out an exception to Delaney, and that the permissible limits of DES
were to be based on detectability in edible animal tissue."' (Since Bell, the
USDA had began to utilize gas- liquid chromatography to detect residues."'
This method is much more accurate and quicker than the previously used
mouse-uterine test (0.5 ppb vs. 2 ppb).)"9 The 1968 Amendment required a
hearing before a compound could be withdrawn from the market. "0 The
"'It was not until 1971 that the use of DES was discovered to cause an increased incidence of
vaginal carcinoma after being administered to the mothers in order to maintain a successful
pregnancy. Greenwald, Barlow, Niasca and Burnett, Vaginal Cancer After Maternal Treatment with
Synthetic Estrogens, 285 NEw ENG. J. MED. 390 (1971); Herbst, Kurman, Scully and Poskanzer,
Clear- Cell Adenocarcinoma of the Genital Tract in Young Females, 287 NEw ENG. J. MED. 1259 (1972).
There was some evidence that DES did cause cancer in animals. Bell, 366 F.2d at 179.
"'Bell, 366 F.2d at 181.
"'id.
"3Section 505(e) of the Act allows FDA to deny any unsafe drug access to the marketplace. 21
U.S.C. § 355(e) (1967).
"'The FDA may use the general safety provisions or Delaney Clause and has often alterna-
ted between the two in regulating carcinogenic substances. See supra note 95 and accompanying
text.
"15lt has been noted that Congress places a heavy burden upon an administrator to explain
the basis for allowing the continued use of a carcinogenic substance. See Environmental De-
fense Fund, Inc. v. Ruckelshaus, 439 F.2d 584, 596 (D.C. Cir. 1971) (case involved DDT but men-
tioned the Delaney Amendment by name).
"6495 F.2d 975 (D.C. Cir. 1974).
"1ld. at 979
"18d.
119d. at 979 n. 6 (GLC sensitivity).
1'21 U.S.C. § 360(c)(3)(e) (1970) (notice and opportunity for Journal hearing).
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FDA asked for and received materials from manufacturers concerning
safety; based on this information it was decided that there was no genuine
issue of fact and denied the hearing. 1l
The court found the FDA in error for two reasons. First, since the Act al-
lows for summary withdrawal if the Secretary finds imminent danger to
public health, the finding must be made by the Secretary and not delegated
to the Commissioner.m The FDA had stated in its finding that the NADA
withdrawal was a regulatory matter and that DES did not present a public
health hazard. The court also found error because the FDA should have
given the manufacturers notice of the results and time to respond as re-
quired by due process of law. 124 Although tests were available to determine if
there were DES residues present, the FDA was precluded from using the
data because they had not yet been approved by the Secretary; the mouse-
uterine test failed to detect these levels. 12
Once again the FDA employed the General Safety Clause. in The court
found that since the FDA desired to withdraw the drug, it had the initial bur-
den of coming forward with evidence showing a link between the residue
and safety. w The court then found that facts as to safety-which "inevitably
means calculating whether the benefits which the drug produces outweigh
the costs of its restricted use" - were not established by the FDA. 2 Hess &
Clark did not, however, address the procedures which the FDA used to set
assay requirements under the DES Proviso; the court implicitly accepted the
FDA's expertise in this area. 11 A companion case reaffirmed that the FDA's
notice and due process procedures were in error in denying a hearing on
m37 Fed. Reg. 15,747 (1962); Hess & Clark, 495 F.2d at 980.
'z7rhe Secretary could not delegate the finding of "imminent hazard to the health of man".
495 F.2d at 982, citing 21 U.S.C. § 360b(e)(1) (1970).
w38 Fed. Reg. 10,485, 10,488 (1973) (order withdrawing FDA approval of NADA's for DES
implants).
124Hess & Clark, 495 F.2d at 994.
1251d. at 991 (§ 512(d)(1)(H) specifically requires approval of method by the Secretary).
1261d. See 21 U.S.C. § 360b(e)(1)(B) (1969).
"
2Hess & Clark, 495 F.2d at 993. In a later decision, the same court found that the FDA had
met its initial burden of coming forward with evidence of a substance's safety, and that its con-
clusion was supported with substantial evidence. Rhone-Poulenc, Inc., Hess & Clark Div. v.
FDA, 636 F.2d 750, 753 (D.C. Cir. 1980).
111495 F.2d at 993-4.
'"Id. (Noting that the relationship between the residues and safety were based on the nature
and amount of the residues not their detection methods).
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DES feed pre-mixes. 0 These early cases reinforced the FDA's desire for pro-
cedures to alleviate uncertainties in evaluating and designating assays pur-
suant to the DES Proviso.
In 1973 the FDA published notice in the Federal Register to promulgate
new assay rules; these were later codified in 1977.131 These regulations, how-
ever, did not settle the DES controversy. The six-step review process, as pro-
posed, incorporated the Mantel-Bryan paradigm which was designed to
predict the risk of cancer due to low level exposure to carcinogens. 132 The fi-
nal regulations contained significant innovations to the method.I3
In American Health Institute v. FDA, 3 The American Health Institute (AHI)
sought to stay the effective date of the regulations because proper rulemak-
ing procedures employing notice and comment had not occurred. Specifi-
cally, AHI contended that the regulations were unlawful because they un-
necessarily broadened the scope of the Delaney Clause and because they
precluded the use of a compound unless an assay existed which was sensi-
tive enough to detect residues at the theoretically (Mantel-Bryan) safe
levels.135 The court found the agency's notice and comment procedures, as
well as its definition and explanation of the criteria and procedures for evalu-
ation of carcinogenic residues, faulty. '3 The FDA promptly published pro-
posed rules in the Federal Register which have collectively come to be
laChemetron Corp. v. U.S. Dep't of Health Educ. & Welfare, 495 F.2d 995 (D.C.Cir. 1974).
13142 Fed. Reg. 10,412 (1977) (Procedures for evaluation of assays used to assess risk of unde-
tected residues).
'The Mantel-Bryan approach allows for the estimation of a level of a specific carcinogen
that would lead to a non-detectible increase in cancer rates during experimentation. Mantel and
Bryan, Safety Testing of Carcinogenic Agents, 27 J. NATrL CANCER INST. 455 (1961) (General ap-
proach); Mantel, Improved Mantel-Bryan Procedure for "Safety" Testing of Carcinogens, 35 CANcER
REsEARcH 865 (1975). See infra notes 270-71 and accompanying text (full discussion of basis of
procedures). See infra notes 235-243 and accompanying text (Quantitative Risk Assessment pro-
cedures).
13Commissioner set forth proposed rules, using the method described in the 1961 Mantel
and Bryan Paper for comment on July 19, 1973. 38 Fed. Reg. 19,226 (1973). Final regulations
were promulgated February 22, 1977. 42 Fed. Reg. 10,412 (1977). These regulations, however,
employed methods found in the 1975 Mantel and Bryan paper. See supra note 132.
re[Transfer Binder 1978] Food Drug Cosm. L. Rep. (CCH) 38,154 (D.D.C. Feb. 8, 1978).
AHI claimed FDA violated § 551 of the Administrative Procedure Act which prescribes in formal
notice and comment rulemaking.
mid. at 38,563.
'Mld. at 38,564. The court according to the standard of review set out in § 706(2)(B) of the
Administrative Procedure Act found the FDA's procedures "arbitrary and capricious.",See Citi-
zens To Preserve Overton Park v. Volpe, 401 U.S. 402 (1971); Burlington Trucklines v. U.S., 371
U.S. 156 (1962) (standards for review of agency rulemaking procedures).
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known as the Sensitivity of Method (SOM) Proposal.137 They contain elabo-
rate procedures for evaluating carcinogenic risk, the technical aspects of
which require a more extensive discussion of carcinogenesis.Im
While litigation concerning new animal drugs has provided some insight
into the scope of Delaney, litigation concerning the Colors Amendment 1
has also shed some light on the subject. Color additives have been more
heavily scrutinized under Delaney than food additives or new animal drugs
because they lack serious social benefits and are utilized merely as aesthetic
agents.401 In general FDA has been more active in banning carcinogenic color
additives. In order for the Delaney Amendment to apply, the additive must
adhere to the statutory definition; its primary purpose is to impart color to
food, and not be exempted. 141 These determinations may be made by either
the USDA or FDA. 4 Delaney coverage of these substances has been incon-
sistent. A 1976 case reaffirmed the doctrine that FDA has discretion in decid-
ing to use Delaney or the General Safety Clause to ban a carcinogenic color
additive. 1
Beginning in 1979, the court's interpretation of the Delaney Clause in
Monsanto Company v. Kennedy1" began a movement toward a more realistic
"'Chernical Compounds in Food-Producing Animals, 44 Fed. Reg. 17.070 (1979) (rules es-
tablishing criteria to determine chemical residues in animal tissue): See Evaluating Assays, supra
note 48. Id. See generally Norcross, Sensitivity of Method - A Wave of the Future, 35 FooD DRUG
CoSM. L.J. 342 (1980); Dexler, The Impact of Senstitiy of Method on Food Regulation, 35 FOOD DRUG
CosM. L.J. 349 (1980); Becker, Sensitivity of Method - Legal Implications, 35 FOOD DRUG CosM. L.J.
355 (1980). Those interested in examining the criteria should consult FDA's "Redbook" and
Good Laboratory Practices regulations. See 21 C.F.R. Pt. 58 (1987).
laChemical Compounds in Food-Producing Animals; availability of new threshold assess-
ment criteria for guidelines, 47 Fed. Reg. 4,972 (1982) (notice of revised evaluation system). See
Evaluating Assays supra note 48 and accompanying text (full discussion). See also infra note 217
and accompanying text.
1321 U.S.C. § 376 (1970).
14FDA has banned the use of many color additives such as carbon black (41 Fed. Reg. 41,857
(1976)), graphite (42 Fed. Reg. 60,734 (1977)), and FD&C Yellow No. 1 (42 Fed. Reg. 62,478
(1977)). It also has attempted to put warning labels on some coal-tar hair dyes. See 44 Fed. Reg.
59,513 (1979). Food additives are often used to preserve food for transport and longer shelf life,
color additives are used mainly for their aesthetic values. Accord Matson, Scientific Judgement in
Law and Regulation, 15 FOOD DRUG CosM. L.J. 70 (1960).
"'Color additives are defined in 21 U.S.C. § 321(t) (1970) and do not include pesticides or
substances that are added for purposes other than coloring. See 21 C.F.R. § 70.3(g) (1985) (pur-
poses other than coloring).
'
0 See Public Citizen v. Foreman, 471 F. Supp. 586, 594 (D.D.C. 1979) (court held that nitrite
use in bacon was not primarily to fix color and pursuant to the Federal Meat Inspection Act, 21
U.S.C. § 621 (1907)(revised 1967), the U.S.D.A. had primary jurisdiction.
'Certified Color Manufactures v. Matthews, 543 F.2d 284 (D.C. Cir. 1977) (termination of
provisional listing of FD&C Red No. 2).
1-613 F.2d 947 (D.C. Cir. 1979).
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view of the Clause. The case arose after the Commissioner published regula-
tions setting tolerance levels of acrylonitrile monomer in plastic beverage
containers pursuant to the General Safety Clause.' The FDA projected that
these levels would be exceeded by the manufacturer's product. 1" The manu-
facturer contended that the monomer left after formulation and curing was
firmly bound and that it would not migrate from the container to the food
under conditions of intended use. - The court found that the Commissioner
did have the discretion to issue technology-forcing provisions when pro-
mulgating food safety regulations, but that FDA's projections were based on
insufficient data. 14 More importantly, however, it found that the statutory
definition of "food additive" could be satisfied by the second law of thermo-
dynamics (i.e. diffusion).4 9
The Monsanto court set forth a two prong test consisting of component
and safety elements."5 First, the intended use of the substance must be rea-
sonably expected to result in its becoming a component of the food.' Sec-
ondly, based on congressional intent, the amount to be found must be sig-
nificant, i.e., not de minimis."s2 This does not require that the amount present
be toxicologically significant, but that the level may even be based upon a
prediction founded on reliable data.13
The finding of a de minimis standard for the definition of food additive im-
mediately raised questions as to the viability of the Delaney per se or zero
tolerance cancer prohibition. ' The court's finding of inferred statutory in-
"'Acrylonitrile is used as a monomer in the making of plastics. It has been found to be carcin-
ogenic. See CASARETr & DOULL, supra note 5, at 532. Indirect additives: Polymers, 42 Fed. Reg.
48,528 (1977). Commissioner originally set migratable (unpolymerized acrylonitrile) levels at 80
ppb; later, after it was learned that acrylonitrile was toxic to laboratory animals, its use in bever-
age containers was banned completely.
"'Monsanto, 613 F.2d at 951.
471d. at 953.
14Id.; see infra note 232 and accompanying text (technology-forcing procedures).
14613 F.2d at 955.
"'DId.
15Id.
"'Id. at 955 n. 26 (citing cases where statutes did not apply to de minimis situations).
"ld. Commissioner must base his decision on reliable data but has discretion to appraise the
public health and welfare. If circumstances exist he may decline to regulate de minimis situa-
tions.
I'AAlthough Monsanto only dealt with the safety clause the court seemed to dispose of de
minimis risk with such dispatch one wonders if the same argument could have been made for de
minimis levels of carcinogenic food additives or drug residues left on edible tissue of animals. See
infra notes 161-172 and accompanying text (FDA proposed to deal with drug residues).
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tent against regulating insignificant levels runs contrary to the prior belief
that Delaney would not tolerate any carcinogenic risk.
The Monsanto decision clearly begs the question, "Is the DES Proviso the
only exception to Delaney?" Many commentators believe that it is not. ' s
Analysis of the legislative history reveals inconsistencies, with scientists ad-
vocating that some sort of dose-response standard is required' 1 and the rest
of the population intimidated by the seemingly unconquerable cancer
threat. 5 The underpinnings of the Delaney Clause are based on the concep-
tion that no threshold dose is able to be found for carcinogens. 1- A de minimis
rule would seem to imply that there is. The FDA's use of Mantel-Bryan's
model would also encourage this result.
If Monsanto did not lead to, it certainly contributed to, the 1982 publishing
of the advanced notice of proposed rulemaking pertaining to food additives
by the FDA.'19 The FDA notice set forth three approaches for comments.
These were the constituent, de minimis, and sensitivity-of-method ap-
proaches.161 The constituents approach would preclude application of the
Delaney Clause based on the biologic reactivity of the whole additive as
compared to its constituents: for Delaney to apply the additive on the whole
would have to be found to induce cancer in animals.' 61 Individual constitu-
ents would not be banned even if they are carcinogenic unless they render
the whole additive carcinogenic. On a biological basis this approach in prac-
tice rules out indirect (epigenetic) carcinogens. 16 This approach also has a
"functional component"; i.e., only if the constituent is found to be functional
will Delaney apply. 16 Of course, one of the major limitations of this ap-
proach deals with classification of constituents. In practice it is difficult to
"5See Merrill, Risk-Benefit Decisionmaking by the Food and Drug Administration, 45 GEO. WASH. L.
REv. 994 (1977); Henteleff, "Modernizing" the Delaney Clause, 38 FOOD DRUG COsM. L.J. 147 (1983).
"'Supra note 72 and accompanying text (NAS 1961 Report).
lx'Supra note 12 and accompanying text (1950-53 Delaney hearings).
w'his concept is known as the "one-hit" theory of carcinogenisis. See infra note 201 and ac-
companying text.
1"147 Fed. Reg. 14,464 (1982) (Revised policy for regulating carcinogenic chemicals in food
and color additives).
1601d.
"'An additive may contain many other substances besides the actual preservative, colorant
or other functional component. These include residual reactants, unreacted intermediates, cat-
alysts, solvents and other manufacturing aids; as well as products from co-reactions and chemi-
cal degradations. See 47 Fed. Reg. 14,464, 14,468 (1982).
162See infra notes 201-226 and accompanying text (mechanisms of carcinogencity).
"rTechnically non functional substances found in food additives/colors would be considered
"constituents" rather than "additives". 47 Fed. Reg. 14,464, 14,468 (1982).
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determine which is functional and which is not; there is also the serious sci-
entific consideration of how the additive biologically reacts once ingested.1I"
The second approach follows the Monsanto finding of de minimis: the Dela-
ney Amendment would not apply if the level of the additive is so negligible
that it presents no public health concern. l De minimis approaches have been
used with other FFDCA provisions concerning adulteration. 16 This ap-
proach would seem to require some method of risk assessment to determine
the de minimis level. This approach would attempt to negate flaws of the De-
laney Amendment found in its original form. 16 7
The third approach is based on the 1979 proposed regulations'6 and is de-
rived from the DES Proviso. 1 The sensitivity-of-method approach has been
touted by many, mainly because it is administratively workable and based
upon a rather solid scientific foundation.170 This approach incorporates a
conservative maximum risk of cancer equal to one in one million over the
lifetime of a human being. 'n The FDA also seems to favor this approach out
of the three and has even revised the threshold assessment criteria from the
previous regulations. 17 By announcing this proposed change in policy, the
FDA has opened the door to changes regarding the regulation of carcino-
gens in food.
In 1983, Senator Orrin Hatch, Chairman of the Senate Labor and Human
Resources Committee, presided over hearings that were designed to ad-
'"The most important consideration deals with the overall carcinogenic activity of the con-
stituent. The constituent may act as a promoter, it may be carcinogenic alone, or it may have no
impact on the carcinogenicity of the additive per se, but enhance the carcinogenicity of another
compound. See Principles, supra note 5.; See also Infra note 207 and accompanying text (pro-
moters and initiators).
'6613 F.2d at 955; 47 Fed. Reg. at 14,467 (1982).
'"See U.S. v. 1,500 Cases More or Less Tomato Paste, 236 F.2d 208, 215 (7th Cir. 1956) (insect
fragments "were so low that they are regarded... as insignificant or of no consequence", using
402(a)(3)); U.S. v. General Foods Corp., 446 F. Supp. 740 (N.D. N.Y.) in affd 591 F.2d 1332 (2d
Cir. 1978) (presence of mold on food processing machinery was de minimis).
"See supra notes 188-223 and accompanying text.
'"44 Fed. Reg. 17070 (1979) (SOM regulations); Evaluating Assay, supra note 48.
'"Supra notes 91-93 and accompanying text.
""SOM is administrately workable because the substance would be deemed safe if its levels
could not be measured, 44 Fed. Reg. 17,070 (1979). But current technology demonstrates that
detection limits are now so low, that the compound is effectively banned.
'"SOM uses the Mantel-Bryan Approach which utilizes a risk level of 10 -6 limit; i.e., the level
at which one in one million people may be expected to contract cancer if exposed to the chemi-
cal. Infra note 270 and accompanying text.
1'47 Fed. Reg. 4,972 (1982) (revised threshold criteria requiring the use of the most sensitive
detection methods as a technology-forcing policy).
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dress alternatives to the Delaney Amendment. 11 While the product of these
meetings has yet to be fully appreciated, the fact that they were held is sig-
nificant. After twenty-five years, the shortfalls of the Delaney Clause were
finally being addressed.17'
To further support the desire for a change in the regulation of carcinogens
in food, the Sixth Circuit adopted the FDA's constituents approach in Scott v.
FDA."' Scott dealt with the permanent listing and continued use of Green
No. 5, which is manufactured from p-toluidine, a known carcinogen.176 The
court found that although the color may contain traces of its carcinogenic
intermediate and impurities, the additive as a whole should be tested. 77 It
also found that the FDA did not abuse its discretion in finding the color not
within the scope of Delaney, citing Monsanto.17 There was also found to be
no reasonable risk of harm caused by the presence of p-toluidine in the
color. '
One technical aspect that the FDA has narrowly avoided in litigation in
applying the Delaney is the concept of the "appropriateness" of the test to
measure a chemical's ability to induce cancer. The text of the clause specifi-
cally mandates carcinogenic evidence as derived from animal experiments
or incidence in man.110 The FDA has avoided the issues of how much and
what sort of animal tests are required. Some documentation has been
present from the inception of the clause and has been reinforced by FDA
publications."', One test that has never been held adequate is mutagenicity
data, derived from in vitro assays which are specifically sensitive to detect
'"Hearings on Food Safety Before the Committee on Labor and Human Resources, 98th Cong. 1st
Sess. (une 8-10, 1983).
"'The Food Safety Hearings stimulated a flurry of bills all designed to modify the Delaney
Clause. See Silverglade, The Risks of Risk Assessment and Risk-Benefit Analysis, 38 FOOD DRUG
Cosm. L.J. 318 (1983) (giving a summary and evaluation of bills submitted in 1983). See also S.
Rep. No. 1938, 98th Cong. 1st Sess.,129 CONG. R c. 13778 (1983) (bill following the de minimis
approach).
'728 F.2d 322 (6th Cir. 1984).
16FD&C Green No. 5 has p-toluidine as an unavoidable impurity, thus compound has been
found to be carcinogenic. Id. at 323.
77The court seemed to follow the "constituents approach" as set forth by the FDA regula-
tions. Id. at 325. See generally 47 Fed. Reg. 14,464 (1982).
"728 F.2d at 325 (6th Cir. 1984).
17Id.
'ODelaney requires that the compound will not be found safe "if it is found, after the appro-
priate tests" to induce cancer in man or animals. 21 U.S.C. §§ 348, 360b, 376 (1970).
"'Current testing criteria are outlined in U.S. FDA, TOXICOLOGICAL PRINCIPLES FOR THE SAFETY
ASSESSMENT OF DIRECr FOOD ADDTIVES AND COLOR ADDMVES USED IN FOOD (1982) [Hereinafter
Redbook] This publication contains extensive sections on assessment of safety, guidelines for
toxicological tests, adequacy of tests and decision-making.
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alteration in DNA.' 1 Despite its sensitivity, the test has the tendency to elicit
false negatives or false positives as determined by follow-up animal stu-
dies. 193In terms of a carcinogenic model, it is thus best left for screening pur-
poses. l 4
What may be gleaned from this discussion of the legislative history and
judicial interpretation of the Delaney Clause is that the clause is seldom
used. The FDA frequently opts to use the General Safety Clause, and even
when Delaney is used there is a tendency to avoid full application. From.the
beginning, the FDA's attempt to implement Delaney can be described as a
futile attempt to place a strict regulation on a subject matter that is in contin-
uous metamorphosis.
The technical short-comings of the Delaney Amendment are the principle
reason for its falling into disfavor at the present time. While an excellent
statement of public policy,'8 it completely fails as a regulation designed to
facilitate control of biological processes. To evaluate the applicability of fu-
ture changes to the Delaney Clause and to make rational decisions based on
that evaluation requires a clearer understanding of the cancer process.
III. Principles and Evaluation of Carcinogenesis
The reason the Delaney Clause has been such a difficult law to implement
stems from the subject matter to which it relates. The cancer process is a
multistage and multi-factorial event. If one considers biological homeostasis
in continuum, the induction of cancer may take place at one instant, but
'
5 Infra note 230 and accompanying text (mutagenicity and the Ames test).
'15 False negatives involve data derived from animal studies where the dose of the compound
was inadequate, the study did not last long enough or the species was resistant. False positives
usually are presented by doses (given that are physiologically not tolerated), the increased inci-
dence of spontaneous tumors, or chemical impurities. Infra note 201-206 and accompanying text
(mechanisms of carcinogenicity). See also Oser, An Assessment of the Delaney Clause After 15 Years,
29 FOOD DRUG COSM. L.J. 201, 207 (1974).
'$Principles, supra note 5, at 10,424; See Editorial, "Delaney Amendment" 1 PREvENTATIVE MEDI-
CINE 292 (1972); Stokinger, Sanity in Research and Evaluation of Environmental Health, 174 SCIENCE
662 (1971) (discussions on "appropriateness" of tests).
'See Hutt, Public Policy Issues in Regulating Carcinogens in Food, 33 FOOD DRUG COSM. L.J. 541
(1978). The author points out that the Delaney Clause was never meant to be a statement of
scientific truth but rather announcement of public policy. This may be entirely correct but in the
regulation of such things as carcinogens the scientific rationale cannot be secondary consider-
ation without encountering serious problems in implementation.
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there is usually no response until some later time. 8 Manifestation of the car-
cinogenic response results from and is affected by a variety of biologic fac-
tors.
In 1982, FDA published toxicological principles for the safety assessment
of food additives'- and in 1985 the Office of Science and Technology Policy
set forth a review of chemical carcinogenesis;M these documents provided
in-depth analysis of this rather complex process. The focus of this section is
to present the material required to understand the procedures and goals of
regulating carcinogens in food. Also presented will be a review of current
risk assessment methods which provide a more realistic approach to regulat-
ing food additives and carcinogens.
A. Cancer Process and the Delaney Clause
In the 15th Century, Paracelsus noted, "All things are poisonous, for
there is nothing without poisonous qualities. It is only the dose which makes
a thing a poison." (Paracelsus, 1493-1541).'8 This quote highlights the most
important concept in the regulation of toxins and carcinogens, namely that
everything may be poisonous and may have the potential to cause cancer,
including compounds essential to human life.' 9 The FDA's regulation of ad-
ditives and animal drugs purports to cover only a small portion of the wide
spectrum of chemicals to which man is exposed; the Delaney Clause nar-
rows this range even further by focusing on substances ingested by man or
animals. 19
'8Homeostasis may be described as the stability of an organism to maintain bodily functions
in a maximal and controlled manner. In relation to cancer, an agent may cause a lesion that is
repaired by the organism or due to homeostatic mechanisms does not present itself until a much
later time. See generally DoRIANs PocErT MEDICAL DIcnoNARY 328 (23d ed. 1982). For a general
discussion of these principles, see CASARETr & DOULL, supra note 5, at 84-138 (chemical carcino-
gens); PRINCIPLES OF DRUG AcrIoN, supra note 24 at 667-702.
'87Evaluating Assays, supra note 48.
'3See supra note 181.
'8CASAEr & DOULiL, supra note 5, at title page. (Paracelsus, 1493-1541)
19' Proteins and minerals such as tryptophan, selenium, calcium as well as endogenous hor-
mones all may cause cancer if ingested at the appropriate dose. See generally Article of Faith, supra
note 31, at 589; Martin, The Delaney Clause and Zero Risk Tolerance, 34 FOOD DRUG CosM. L.J. 43
(1979).
'
91The FDA has jurisdiction to regulate all foods, drugs, cosmetics and medical devices. This
subject matter covers all possible routes of exposure i.e. not only ingestion but dermal applica-
tions, etc. See 21 U.S.C. §§ 348, 360b, and 376 (1970). See also 21 U.S.C. § 331 (1970) (prohibiting
the introduction into interstate commerce of adulterated foods, drugs, devices or cosmetics).
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Since its inception this clause has been the subject of scientific attack,
mainly because it ignores a basic tenet in pharmacology/toxicology; it
refuses to account for any dose-response relationship.'1 This relationship
was contemplated by the drafters but due to the overwhelming fear of the
cancer of the time, Congress deemed it necessary to ban all carcinogens. 1
Assuming the Delaney Committee's premise that it was impossible to deter-
mine a threshold dose (which in some instances does seem to be supported
by evidence), the Amendment's coverage was drafted too narrowly by only
covering food additives, and not pesticides or natural constituents.1 9 Con-
gress also carved two broad exceptions: substances listed as GRAS and
Prior-Sanctioned Ingredients.'" In terms of total risk, then, the Delaney
Clause eliminated very little. Perhaps the best thing that may be said is that
the Amendment fostered the public awareness that all things put into the
environment and our food tend to return. Historically, this public aware-
ness began to appear shortly after Rachel Carson published Silent Spring'
lfThe Delaney Clause precludes any food additive from being found safe if it has been found
to induce cancer in man or animals. This ban does not consider any dose element. This concept
is known as the "one-hit" theory where one molecule of the carcinogenic substance causes ir-
reparable damage regardless of dose. While this may be true, current research has shown that
some carcinogens do act in a dose-related manner. Figure 1 below illustrates this type of mecha-
nism.
1.00
P(d) =
Probability
of response
at dose d
0
d = dose
Fig 1. - A dose-response curve.
The abscissa represents dose and the ordinate the probability of response at the given
dose. From such studies dose relate carcinogenesis may be shown. Van Ryzin, Quantita-
tive Risk Assessment, 22 J. OCCUATIONALMEU. 321, 322-23 (1981); infra note 202 and accom-
panying text (genetic and epigenetic carcinogens).
1I9he "one-hit" theory of carcinogenesis is still a viable theory today, but in the 1950"s there
were few other alternatives. At the time determination of safe levels of carcinogens was for the
most part impossible. See Article of Faith, supra note 31 and accompanying text, for current risk
assessment models showing how such determinations may be made. Infra note 201 and accom-
panying text.
"See supra text accompanying notes 3 and 58.
19 See supra notes 51-52 and accompanying text.
19R. CARSON, StLENT SPRING (1962). This book drew attention to the interaction of chemicals
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and was also evident at the Delaney hearings.19 Everything from the steaks
we barbecue to the bread we bake may contain cancer-causing agents, pro-
vided we are exposed to a high enough level or wait a long enough time.1 In
fact, prolonged physical irritation has been shown to induce cancer. This is
the purported mechanism behind the mesotheliomas caused by asbestos. 9
The Delaney Committee's refusal to find a cancer threshold was based on
the concept known as the "one-hit" theory."O Briefly, this theory states that
to induce carcinogenesis, all that is required is exposure to one molecule.21
The "one-hit" theory has never been disproved but it must be qualified.
First, by using this theory one is referring to a specific type of carcinogenic
mechanism, i.e., genetic or direct carcinogens.I For such a significant event
with biological systems and set forth the notion that once something is put into the environ-
ment it is not gone forever.
"'The Delaney Hearings may be characterized as a way to halt the indiscriminate use of haz-
ardous chemicals in the nations food supply. See Delaney Proviso, supra note 26, at 557 (describ-
ing the tenor of the Delaney proceedings).
1 The grilling of animal tissue or the burning of any organic matter forms releases
benzo(A)pyrene, a potent animal carcinogen. See CAsAREr & DOULL, supra note 5, at 92. Wheat
is usually contaminated with some level of alfatoxins, which are a group of toxins produced
from the mold Aspergillus flavus. Alfatoxin B1 is known to be a potent hepatotoxin and its pres-
ence in wheat is practically unavoidable. This compound is regulated by the FDA under the
General Safety Clause (§ 401(a)) and wheat is found to be unsafe at 15 ppb. It should be noted
that the low levels appear to be innocuous, because liver cancer is a relatively rare disease. See
AMERIcAN CANcER Socmar, 1979 FAdTS AND FIGURES (1978); 39 Fed. Reg. 42,748 (1974). These ex-
amples are provided to illustrate that in the right dosage range practically anything may cause
cancer. This extreme position that must be qualified. The onset of toxic effects in many cases
often preclude the occurrence of a carcinogenic event, thus one may be poisoned before bioac-
cumulating a dose high enough to cause cancer. Carcinogens that deserve scrutiny and regula-
tion usually work by a particular (direct) molecular mechanism. Infra notes 201-206 and accom-
panying text. See generally, CASARET & DOULL, supra note 5, at 93. But see supra note 193.
199 his concept is known as the "Physical Carcinogen Theory" where the elicitation of an
inflammatory response may induce tumor formation and growth. It is by this mechanism that
carcinogens that do not react with DNA or interfere with a more classic physiological pathway
probably work. See Chemical Carcinogens, supra note 5, at 10,386. This is the proported cause of
mesotheliomas arising from asbestos exposure. Kammerstein and Churg, Pathology of Car-
cinoma of the Lung Associated with Asbestos Exposure, 30 CANcER 14 (1972).
mnThe term "threshold" is used synonymously with "no effect level", and means the level at
which experiments indicate no increased incidence of tumors over background. See DORLAND'S
PocKET MEDICAL DiCTONARY 679 (23rd ed. 1982).
2iThis theory assumes that each molecule of a substance that enters the organism is free to
interact with DNA or some other functional macromolecule and induce cancer. See Mantel and
Schneiderman, Estimating "Safe Levels, A Hazardous Undertaking, 35 CANCFR REs. 1379, 1382
(1975).
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to take place, a chemical/DNA interaction must occur.m These carcinogens
tend to be highly mutagenic and thus detectable in short-term or in vitro as-
says."" Indirect or epigenetic carcinogens do not have a direct DNA compo-
nent; instead exposure to these substances causes pathologic changes that
facilitate or promote tumor growth by another mechanism.20 This latter
mechanism does allow for a dose-response relationship.
Often when reading regulatory data one will come across the terms initia-
tor and promoter. Initiators sometimes are mistakenly referred to as genetic
carcinogens (described above) but are more correctly defined as agents re-
sponsible for the induction of irreversible alterations in genetic material.207 It
is important to emphasize that just because this event has taken place, one is
not necessarily destined to contract cancer. This may or may not be a one-
shot phenomena, and the process may also depend on dose or co-exposure
to other substances." Initiation is merely one stage of this process, one
(procaranogen) is metabolized into a biologically active agent. Other direct mechanisms may
include viral transformation of oncogenes. Eqigenetic carcinogens (indirect) utilize some sec-
ondary mechanism, such as blockade of a metabolic detoxification pathway. These have the
tendency of causing cancer in a dose dependant manner, i.e., the higher the dose the increase in
incidence of tumors, and are reversible. See generally Chemical Carcinogens, supra note 5.
23n order for the one-hit theory to work the chemical must directly interact with the target
tissue of the animal i.e. a direct or genetic (DNA) mechanism. This is because the one-hit theory
does not lend itself to a dose-response relationship, e.g. theoretically the animal would contract
cancer on the first hit and recovery would be precluded thereafter. It should be noted that a
distinction is being made between incidence of cancer and incidence of tumors. Under the one-
hit scheme the incidence of tumors would be dose-dependent, i.e., each molecule that enters
induces one new tumor. This rationale like the cancer process it describes is not foolproof.
Many argue that the one-hit theory is the predominant mechanism because incidence of cancer
is dependent on tumor latency (time from DNA alteration to presentation of cancer) and thus
with each new hit the latency is shortened. See generally Chemical Carcinogens, supra note 5, at
10,390 (Cancer formation section).
2"'Mutagen" refers to a chemical capable of altering DNA structure. DORLANuS POCKET MED-
iCAL DICTIoNARY 430 (23rd ed. 1982). The cancer process is thought to be initiated by an alteration
in DNA, which then causes uncontrolled cellular proliferation. See CASAREir & DOULL, supra
note 5, at 85-130 (Chemical Carcinogens).
In vitro assays are short term bacterial assays which are capable of measuring a compound's
mutagenic potential. See Ames, McCann and Yamaski, Methods for Detecting Carcinogens and Mu-
tagens with the Salmonella Mammalian Microsome Mutagencity Test, 31 MUTATIoN REs. 347 (1975).
maSee supra note 202.
2Id.
21Initiators may be likened to primary or direct carcinogens, the presence of which is re-
quired for tumor induction. Chemical Carcinogens, supra note 5, at 10,390.
"DNA repair mechanism, metabolic pathways and a species' biologic characteristics may
cause profound variation as to the way a carcinogen will react and the effect that it will have. Id.
at 10,387. See also note 211 and accompanying text (Promoters).
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which may remain latent for years.- But as the number of "initiators" in-
creases (dose or agent) so do the chances that the process will proceed to the
next stage.210 Promoters, on the other hand, do not necessarily cause this sort
of interaction and may be distinguished from epigenetic agents because they
usually do not cause a pathologic change that leads to a direct carcinogenic
event. These substances may act to saturate the detoxification pathways (or
excretion routes) of initiators, inhibit DNA repair mechanisms or promote
cell proliferation by a hormonal mechanisms.21 Figure 2 illustrates this
process, (see page 201 text).
Carcinogenic potency is an elusive term to define and is based on a variety
of factors. In simple terms, it refers to a substance's ability to penetrate the
organism and reach a target site at a concentration sufficient for that com-
pound to cause a carcinogenic event, 2 2 Relevant factors vary from agent to
agent but depend upon the chemical nature of the compound, route of expo-
sure, metabolism, pharmacokinetics and target tissue .2 1 Figure 2 illustrates
this process:
'mLatency or "time-to-tumor" refers to a process called neoplastic progression whereby cel-
lular alteration leads to tumor formation. This state of cellular transition from DNA damage to
tumor formation is often termed "somatic mutation'. See infra note 213 and accompanying text.
The time required for this progression may take years. See generally Chemical Carcinogens, su-
pra note 5, at 10,393.
21 See Chemical Carcinogens, supra note 5, at 10,392.
"'These mechanisms are collectively categorized as host defense mechanisms and may re-
pair or mitigate the chemical insult. Depending on the organism, the chemical, or the dose,
these mechanisms may either stimulate or inhibit carcinogenic insult. Id.
2"Fundamental to this concept is the idea that most carcinogens have a specific target tissue
i.e. a tissue at which tumor induction first occurs. This increased propensity for tumors at one
given site over another may be due to the molecular structure of the compound, a unique aspect
of the tissue, the biological activity of the tissue (presence of metabolic pathways, lack of DNA
repair, or receptor sites) or a combination of these effects. One example of this tissue specificity
is seen with aflatoxin, as previously discussed in note 197. See PRINCIPLES OF DRUG ACTION, supra
note 24, at 667-68.
21"TIhe chemical nature of the agent may predetermine its carcinogenic potential. Polyaro-
matic hydrocarbons such as Benzo(A)pyrene (found in grilled foods) is a chemical with a struc-
ture which identifies it as a carcinogen. The route of exposure may determine if and where a
carcinogen will act. The Delaney clause only deals with ingested foods, but carcinogenic risk
from drugs, foods and cosmetics may be from a number of routes, i.e. inhalation, dermal appli-
cation and intravenous. Metabolism also plays in important role in the carcinogenesis of a com-
pound. From a regulatory point of view, it must be realized that exposure to multiple agents
may alter how one or more of the agents will react by the way the body activates or deactivates
the compound. See Miller, Some Current Perspectives on Chemical Carcinogenesis in Humans and
Experimental Animals: Presidential Address, 38 CANCER RESEAxRCH 1479 (1978) (structure of chemical
carcinogens, metabolism of foreign compounds). See generally CASA r & DOULL, supra note 5,
at 667-702; infra note 291 and accompanying text (Pharmacokinetics).
THE DELANEY CLAUSE
CARCINOGEN OR PROCARCINOGEN
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FIGURE 2. SIMPLIFIED VIEW OF BIOLOGICAL EVENTS INVOLVED
IN CHEMICAL CARCINOGENESIS 214
21 Bull, Experimental Methods for Evaluating the Health Risks Associated with Organic Chemicals in
Drinking Water, 6 Toxic AND ENvm. CHEm. 1 (1982).
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It should be noted that no distinction should be made between benign
and malignant tumors in the regulation of carcinogens. 15 A benign tumor
may be thought of as a site which has undergone uncontrolled cell prolifera-
tion and for some reason has ceased; whether or not the lesion actually be-
comes malignant is unimportant because there has clearly been a cellular
change.216 The prognosis, however, is most often radically different.
The Delaney Clause in present form fails to make any of these biological
distinctions. As an illustration, cyclamates and saccharin were in use prior to
1958 and were GRAS-listed following the enactment of the Food Additives
Bill. 217 Cyclamates were eventually found to be carcinogenic and banned. 218
Despite questionable data and further tests tending to show that it was a
promoter rather than primary carcinogen (initiator), saccharin was pro-
posed to be banned under Delaney in 1977.29 Saccharin was shown to in-
crease incidence of bladder tumors when it was given in combination with
cyclamates.- The public outcry which followed was unprecedented. Sac-
charin was not only a favorite of weight-conscious Americans, but was use-
ful in controlling such conditions as obesity and hyperglycemia. '1 The
FDA's own press release did little to help the credibility of the data, since it
stated that there was no evidence linking it to cancer in humans. This led
Congress to place an 18 month moratorium on the ban.m While comprehen-
sive data has yet to come in, some evidence indicates saccharin is not the
carcinogen it was originally purported to be. m Statistical misinterpretation
has also been implicated in the banning of C & D Red No. 2 under the Gen-
eral Safety Clause.14
2
'See Food and Drug Administration Advisory Committee on Protocols for Safety Evaluation: Panel
on Carcinogenesis Report on Cancer Testing in the Safety Evaluation of Food Additives and Pesticides, 20
ToxcoL. APPL. PHARm. 419 (1971).
216See Problems in the Evaluation of Carcinogenic Hazard From Use of Food Additives, (Sub-
Committee on Carcinogenesis, Food Protection Committee and Food Research Council, NAS-
NRC) 21 CAN'cER REs. 429, 432 (1961) (benign versus malignant tumors). [Hereinafter Food Pro-
tection Committee.]
21724 Fed. Reg. 9.368 (1959) (GRAS listings).
245 Fed. Reg. 61,474 (1980) (Banning of Cyclamates).
21942 Fed. Reg. 19,996 (1977) (Proposed Rules on Saccharin).
tmSupra note 218.
2" Saccharin Ban and Food Safety Policy: Hearings before the Sub-Committee on Health and Scientific
Research of the Senate Committee on Labor and Human Resources, 96th Cong., 1st Sess. 231 (1979).
mSeegenerally Schultz, The Bitter Aftertaste of Saccharin, 40 FOOD DRUG COSM. L.J. 66, 72 (1985).
mSaccharin has been purported to be a promoter rather than direct carcinogen. See CASARE'r
& DOULL, supra note 5, at 116 See also Friedel, National Bladder Conference, 37 CANcER REs. 734
(1977).
24Kirschman, Toxicology - The Exact Use of an Inexact Science, 31 FooD DRUG CosM. L.J. 455
(1976).
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B. Evaluation of Data and Setting Tolerances Based on Carcinogenic Risk
A comparison on Delaney Clause interpretation and current knowledge
of carcinogenesis leads to the conclusion that regulation under this standard
is unworkable. The question then follows what standard should be used to
protect the public from these hazardous substances? The possibility exists
that there may never be a straight-forward standard that will allow regula-
tion of all carcinogens. This is not based on a lack of knowledge alone, but
rather upon the complexities and diversities of the cancer process itself.
Current knowledge suggests that regulation of carcinogens should re-
semble that of compounds regulated by the General Safety Clause, though
utilizing a more conservative approach primarily focusing upon risk.- Risk
is a relative term that requires scientific as well as moral judgments to be
made.26 Because it resists relative risk judgment, the Delaney Clause has
been the focal point of much criticism.'m Scientific judgments guided by pub-
lic policy considerations are not difficult to perform, and if correct proce-
dures are set forth, they may in fact become routine.
Quantitative risk assessment procedures may allow for these judg-
ments.- Specifically one should consider the compound 9 and its uses.' If,
for example, an additive or any substance subject to regulation performs no
useful purpose and preliminary data tends to show that it is a potent carcino-
n
1
rhis proposal deals with the sort of risk-benefit analysis found in the General Safety
Clause, but is modified to account for the biological mechanisms of cancer. See 21 U.S.C. § 342
(as amended 1970). Carcinogens by nature require more strict scrutiny and assurance that the
risk of harm is minimal; this requires a greater margin of safety to be used in the calculation of
safe levels. Infra note 275 and accompanying text (margin of safety).
6See Hut, Public Policy Issues in Regulating Carcinogens in Food, 33 FOOD DRUG CosM. L.J. 541
(1978).
'See Matson, Scientific Judgment in Law and Regulation, 15 FooD DRUG CosM. L.J. 70 (1960);
Coon, The Delaney Clause, 2 PREVENTATIVE MEDCIME 150(1973).
m See generally Interdisciplinary Panel on Carcinogenicity, Criteria for Evidence of Chemical Car-
cinogenicity, 225 SCIENCE 682 (1984); Quantitative Risk Assessment, 18 Food CosM. TOXcoLoGY 711
(1980). [Hereinafter Quantitative Risk Assessment].
mSupra note 213 and accompanying text (evaluation of chemical structure).
z 3Use analysis not only includes the extent and manner which a compound is used in eva-
luating food, or the prevalence of the compound in a given foodstuff, but also an estimation of
the population at risk, i.e. conditions of exposure, number of persons affected and age of those
affected. Quantitative Risk Assessment, supra note 228.
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gen (e.g., in the range of 10-3)31 zero tolerance may be a rational alternative.m
At this point technological and economic feasibility may also be considered.
However, since this is a public health problem, present technology-forcing
measures should not be ruled out.3 Once it has been shown that a carcino-
gen is worthy of regulation, one may then proceed to predict "a safe" level. 4
Quantitative risk assessment evaluates chemicals and other agents on a
case-by-case basis using mathematical models. 3 These mathematical
models utilize data points from observed exposure levels to formulate dose-
response-type curves which may then be used to predict risk at lower expo-
sures.2 The use of a particular model or curve can be justified by the "mathe-
matical" fit to the available data points.237 The use of these types of
procedures is based upon the understanding that the mathematical curves
are reflective of the biological factors that are present when an organism is
exposed to a carcinogen.
[The] biological factors which may play important roles in the risk
assessment are (1) dose of the material at the sensitive tissue; (2) the
sensitive tissue(s) itself; (3) the nature of the response(s); (4) rates
23Generally speaking a negative exponent is used to denote "one in a..." chance of con-
tracting cancer e.g. 10-1 - one in a thousand. This risk is considered by most to be quite high, the
benchmark seem to be 10-6 (one in a million) as proposed by Mantel and Bryan in 1961. A life-
time risk at this level would roughly correspond to three additional cancer deaths in the U.S. per
year. Id. at 713. See Mantel and Bryan, "Safety" Testing of Carcinogenic Agents, 27 J.NArL CANcER
INST. 455 (1961).
z1rhus the rationale of the Delaney Amendment may in fact be applicable in those rare in-
stances where the chemical is a potent carcinogen (genetic) with little or no beneficial use and
with the potential to expose a great number of people. See generally Kennedy, Priority Setting in
the Real World, 32 FOOD DRUG COSM. L.J. 527, 531 (1977).
nyThis concept has been previously used in the setting of safe levels of "added" substances.
See Monsanto, 613 F.2d at 954. (If the Commissioner, in his review estimated an acceptable acry-
lonitrile level he could issue a statement prescribing it. It would then be up to the industry to
meet an acceptable level).
2These levels may be predicted on the basis of Virtually Safe Doses (VSD's). Infra note 258
and accompanying text.
2
mQuantitative risk assessment is not to be restricted solely to chemicals, it is currently being
used to evaluate chemicals, biologicals, viral particles and radiation levels, all of which may
induce cancer and could be found in food. Principles, supra note 5, at 10,383-19,387. Because the
mechanisms of cancer may vary, case-by-case evaluation of separate (or related) compounds is
necessary. See Interdisciplinary Panel on Carcinogenicity, Criteria for Evidence of Chemical Car-
cinogenicity, 225 SCIENCE 682, 683 (1984). (Hereinafter Criteria for Chemical Carcinogenicity].
'See generally Quantitative Risk Assessment, supra note 228.
23
'See Krewski and Van Ryzin, Dose Response Models for Quantal Response Toxicity Data, in:
CURRENT BooK ToPics IN PROBABILrrY AND STAnsncs (1981) [hereinafter Krewski and Van Ryzin];
Van Ryzin, Quantitative Risk Assessment, 22 J. OCCUPATIONAL MED. 321 (1980).
'Occupational Exposure to Ethylene Dibromide, 48 Fed. Reg. 45,956, 45,969 (1983).
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and sites of biotransformation; (5) toxicity of metabolites; (6)
chronicity of the compound (cumulative nature of the material or its
actions); (7) pharmacokinetic distribution; (8) the effect of biological
variables such as age, sex, species and strain of test animals; (9) and
the manner and method of dosing the test animals.
While it may be impossible to fit all of these factors into one model, com-
parisons of different data sets within the various risk assessment procedures
should be made.24
Risk assessment procedures consider data from four sources: chemical as-
says, short-term toxicity tests, chronic animal studies, and epidemiologic
tests.14 1 They follow the general scheme of hazard identification (qualitative
data indicative of carcinogenic activity) exposure assessment (population at
risk at various levels and duration of doses), and mathematical modeling.424
These procedures attempt to translate biological activity into safe dose levels
based on data derived from animals and/or previous human exposure.243
The criteria for animal studies that may be used for risk assessment is
strictly a matter of scientific judgment. 2" The function and validity of such
tests are impacted by a number of considerations. First, positive results are
found in long-term (chronic) animal studies when administration of the
agent, in adequately designed and conducted experiments, demonstrates
an increased incidence of one or more types of tumors in treated animals as
compared to untreated animals maintained under identical conditions. 24
Further changes in tumor latency2- and numbers of tumors2 7 also tend to be
indicators of carcinogenic potency. 2 Testing should be done under experi-
zwld.
240d.; Silverglade, The Risk of Risk Assessment and Risk-Benefit Analysis, 38 FOOD DRUG COSM.
L.J. 318, 319 (1983).
24
'See Principles, supra note 5, at 10,424.
24w/d.
24These methods are used to translate biological activity into safe doses by using mathemati-
cal models which assign numerical values to the various parameters involved in the toxic or
carcinogenic response. See Van Ryzin, Quantitative Risk Assessment, 22 J. OCCUPATIONAL MED.
321, 322 (1980) (illustration of models).
244Article of Faith, supra note 31, at 589. supra note 181. See Redbook. The Redbook contains
guidelines and explanations of methods that should be used in the execution of appropriate
toxicological tests. It includes such methods as design of pilot studies, selection of dose, and
methods of tumor evaluation. See also 21 C.F.R. Pt. 58 (1985) (FDA Good Laboratory Practices
which standardize research and data collection techniques).
'Criteria for Chemical Carcinogenicity, supra note 235, at 683.
243Supra note 209 and accompanying text.
247Criteria for Chemical Carcinogenicity, supra note 235, at 683.
"4'Food Protection Committee, supra note 216, at 432 (potent and weak carcinogens).
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mental conditions likely to yield maximal tumor incidence.249 Both the scien-
tist and regulator should be aware that other conditions such as stress and
irritation may themselves induce tumor formation.-
Epidemiologic studies, when available, are the only reasonable means of
directly assessing the carcinogenic potential of agents in humans. Studies
are limited by availability and relevance, as well as lack of scientific valida-
tion of results.25' Such studies can be separated into two categories: descrip-
tive (hypothesis generating) and analytical (hypothesis testing).' a The de-
scriptive studies explore the relationship between exposure and tumor
development at specific target sites. m
Analytical studies are designed to test hypothesized relationships and
may be further differentiated into case comparison and cohort studies.-I
Case studies compare past histories of exposure and personal characteristics
of cancer patients with those from similar settings who do not have cancer.2
Cohort studies examine the personal histories and characteristics of a sam-
ple population through time and determine a rate of cancer within that pop-
ulation.-
Once data has been collected from the various studies of risk, assessment
based on dose-response-type curves may be conducted. - The goal of such a
249See generally Nat'l. Toxicology Program Ad Hoc Panel on Chemical Carcinogenesis Testing
and Evaluation (1984) (defining "Maximal Tolerated Dose" (MTD) as the amount of agent
needed to elicit a response without significantly altering the animal's life span).
1Id. See also Principles, supra note 5, at 10,413; supra note 199 and accompanying text (physi-
cial carcinogens).
rePrindples, supra note 5, at 10,420 (limitations of epidemiology).
'-"See generally Criteria for Chemical Carcinogenicity, supra note 235, at 682-683 (types of epide-
miology studies).
mScientific Bases for Identification of Potential Carcinogens and Estimation of Risks, 44 Fed.
Reg. 39,858 (1979).
2MId.
'See generally, Principles, supra note 5, at 10,422.
211Id. Each of these studies evaluate different parameters, i.e. case studies examine cancer
patients in a finite patient population, whereas cohort studies examine a particular population
through time. One should be aware that case studies require a control group (non-exposed
group) while cohort studies require that the exposed group is complete as possible (to detect all
cases possible). See Muir, Limitations and Advantages of Epidemiological Investigations of Environ-
mental Carcinogenesis, 329 N.Y. ACAD. OF ScENcEsANNALS 152 (1979). To one evaluating this data
it is important to ensure that the previously described classification(s) have been made because
misuse of data will lead to erroneous risk determinations. This hazard may only be determined
from extrapolation from higher dosages. Epidemiology studies may, however, indicate the
limit within which a specific type of exposure will affect the incidence of cancer in humans.
Criteria for Chemical Carcinogenicity, supra note 234, at 683.
'Supra note 192 (illustration of Dose-Response Curve, Figure 1).
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procedure is to estimate a Virtually Safe Dose (VSD), which corresponds to a
predetermined low level of increased risk over a spontaneous background
rate. m No one model is preferred; in fact, a variety should be tested to deter-
mine the best mathematical fit for high dose to low dose extrapolation.'"
This method may even permit the application of the One-Hit Theory of car-
cinogenesis.2"
These mathematical models fall into two broad groups: tolerance distribu-
tion and mechanistic models.26' Tolerance (threshold) models are based on
the premise that each individual in the population has a tolerance dose to the
test compound after which a response is seen (e.g., increased incidence of
cancer).262 Mechanistic or stochastic models are based on biological princi-
ples which lead to an expression of the probability of a response at any given
dose.6 Due to the nature of the cancer process, the latter appears to be more
applicable, although threshold modeling is less complex, hence easier to
perform.-
The Mantel-Bryan Methods currently employed by the FDA is techni-
cally a tolerance model, but is rather unique.2 Instead of curve fitting, it uses
a data curve which intentionally lies above the actual dose response curve.m
2mCrump, Guess and Deal, Confidence Intervals and Tests of Hypotheses Concerning Dose Re-
sponse Relations Inferred From Animal Carcinogenicity Data, 33 BioMRrmcs 437 (1977) (determina-
tions of VSD's).
Risk levels may range from 10-' to 10- 1. Cornfield, Carlborg and Van Ryzin, Setting Toler-
ances on the Basis of Mathematical Treatment of Dose-Response Data Extrapolated to Law Doses, in PRO-
CEEDINCSOP THE FIRST INTL. CONGRESS ON TOXICOLOcY 143 (1978) (level of risk values) [Hereinafter
Setting Tolerances]; infra note 270 (Mantel-Bryan Method, Figure 3).
25'See Occupational Exposure to Ethylene Dibromide, 48 Fed. Reg. 45,956, 45,969-970.
"Mathematical fit" is a term used to describe how well the data correlates to the dose-response
curve. Extrapolation is the prediction of risk outside the range of the observed data. Interpola-
tion is the prediction of risk within the range of the observed data.
2Supra note 192 (One-Hit Theory of Carcinogensis).
-lChand and Hoel, A Comparison of Models for Determining Safe Levels of Environmental Agents,
in RELuBaUr AND BIOmEFRY; STATISlICLA ANALYSIS OF LIfElENGTH 381(1974).
W2ld.
26 See Krewski and Van Ryzin, supra note 237, at 201.
'This is because a less rigorous review is required. See Evaluating Assays, supra note 48 at
17,087-17,088 (explanation of Mantel-Bryan Method).
m'Mantel, Bodihar, Brown, Ciminera and Tukey, An Improved Mantel-Bryan Procedure for
"Safety" Testing of Carcinogens, 35 CANCER RESEARcH 865 (1975). [Hereinafter Improved Mantel-
Bryan Procedure].
N6See Peto, Lee and Paige, Statistical Analysis of the Bioassay of Continuous Carcinogens, 26 BR. J.
CANCER 258 (1972) (discussion of Probit (tolerance) Models).
'"This concept is known as "Conservativeness" of procedure where the dose allowed is
lower than the actual VSD. See Setting Tolerances, supra note 258, at 143.
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It also has been modified to account for tumor latency. This method re-
quires the setting of a maximally permissible risk and the "appropriate" stu-
dies2 be performed with a dose-response curve drawn from the data. ° The
pre-setting of a maximum permissible level (usually 106) is a way of provid-
ing a margin of safety for all compounds and thus distinguishes the method
from those which set specific thresholds for each compound. Because it uses
confidence limits of 95 to 99 percent, the longer the experiment, the lower
the upper confidence limit for extrapolation. This tends to increase the safe
level and reward good experimentation.' However, because of technical
'Supra note 208 and accompanying text; Improved Mantel-Bryan Procedure, supra note 265.
2NSupra note 180 and accompanying text.
'Supra note 192 and accompanying text (Dose-Response Curve). The Mantel-Bryan Model
uses a Probit Model which allows for a linear rather than sigmoidal curve. Infra note 271.
"'Figure 3.
z
UCL
d, DOSE d
The UCL is the upper confidence limit which is set at 99%, i.e. 99% of all observed tumors
fall below that dose limit. "S" is the maximally permissible risk, i.e. 10-6, and d, is the
dose corresponding to that risk. At ds there is a 10-6 probability of carcinogenesis.
Schneiderman and Mantel, The Delaney Clause and a Scheme for Rewarding Good Experimen-
tation, 2 PREVENvrvE MEDIcNE 165 (1973). The larger the experiment the lower the UCL,
thus the higher the safe dose. Figure 4.
OUCL
UCL
dhNs  dhsI  dh
DOSE
d h - higher dose; dhs - higher safe doses
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problems with the method (e.g., it tends to over-estimate risk in low dose
ranges), Mantel-Bryan use is declining.2 72 Mechanistic non-threshold
models are more scientifically plausible and have undergone refinements,
which make them the models of choice.7 3 This is because models which in-
corporate the same diverse biological mechanisms as the cancer process are
inherently more accurate.271 Regardless of what model is chosen, the VSD is
multiplied by a safety factor in order to set a safe level. M
Quantitative risk assessment, which utilizes chemical data, animal exper-
iments and epidemologic studies to predict risk of cancer via mathematical
modeling, is based on the sound scientific rationale that all chemicals have
the potential to induce cancer, and that for most carcinogens there is proba-
bly a level which presents a de minimis risk.76 At this time no one model is
favored or in different instances workable over another, but by careful anal-
ysis of the data, accurate assessments may be made. Whether a full merger
with the safety clause is in order is questionable, but there is little sense in
making trivial distinctions as to source ( i.e food additive versus unavoidable
added constituent) when public health is involved. For example, after hav-
ing explored the cancer processes, a person may determine that exposure to
a low level of saccharin may be insignificant in terms of cancer risk compared
to exposure to a slightly higher level of alfatoxins. Granted, control of natu-
ral constituents, pesticide residues and the like are easier to control than
food additives, but this is a problem of risk management not risk assess-
ment. 27 As technology increases and as procedures become more ad-
"5Crump, Theoretical Problems in the Modified Mantel-Bryan Procedure, 33 BioMEsrrmcs 752 (1977)
(model tends to be too conservative); Salsburg, Open Query: Theoretical Problems in the Modified
Mantel-Bryan Procedure, 33 BioMERscs 419 (1977).
2 73Mechanistic models include the One-hit, Multistage and Multi-hit models: These models
assume that once a single cell has been altered, tumor induction occurs. The most frequently
employed model of this category is the Armitage-Doll Model, which takes into account the
multi-stage mechanism of carcinogenesis. This too is a conservative model (similar to the
Mantel-Bryan procedure) with respect to dose setting. See Principles, supra note 5, at 10,438.
"'Id.
v"5his procedure insures that the risk of cancer is minimal, the result of these calculations
being the Acceptable Daily Intake (ADI). This safety factor is designed to account for differences
in interspecies extrapolation and variations in human dietary patterns. Infra note 282 (Problems
with extrapolation). These safety factors have been used for sometime in predicting no observ-
able effect levels (NOEL). See CASARETT & DOULL, supra note 5, at 26 (general discussion of ADI
factors and NOEL).
"
6The author realizes that this risk assessment approach will not be applicable in all circum-
stances, i.e. where the additive or regulated substance is potent and of little societal value. Supra
note 232 and accompanying text. Supra note 218 and text accompanying text (potent versus
weak carcinogens).
"5See Criteria for Chemical Carcinogenicity, supra note 235, at 687 n. 15. (Distinguishes risk as-
1987-881
JOURNAL OF LAW AND HEALTH
vancedml their cost will become negligible as compared to the animal studies
that are now required. 19 Also, as the data in a library of chemicals expands,
the amount of testing required should decrease. Chemical, hence toxicologi-
cal analogy may supplant some of the more basic studies. After confirmatory
studies, the agent may then be regulated based on studies focusing on a spe-
cific organ system or biological factor. While quantitative risk assessment is a
far superior method to the current Delaney Clause, in technology and con-
cept, some regulatory and social difficulties can be foreseen and deserve
consideration.
One such problem concerns "cancer fear." A change in FDA policy with-
out sufficient education/information dissemination to the public could trig-
ger general insecurity. An uninformed citizen could misinterpret the situa-
tion as government irresponsibility. - These fears may be allayed by simple
comparisons of other risks taken in society.21 Adequate assurances that risk
assessments will be conducted appropriately is also beneficial. A fine line
must be drawn, however, to ensure that those informed are not lulled into
thinking that all cancer risk has dissipated rather than that it is being dealt
with responsibly.
A second problem involves extrapolation and concerns both technical
and social issues. Ever since toxicity and carcinogenicity testing began, the
public has doubted the applicability and accuracy of animal data extrapola-
sessment from risk management):
[R]isk management, by definition, begins after risk assessment has determined that a
risk to a human population exists. Whereas "assessment" deals with biological signifi-
cance, "management" deals with the possible alternative regulatory actions. Included in
risk management may be evaluations of costs, feasibilities, risk-benefit ratios, availability
of replacement substances or processes, and the level of risk that is acceptable to the soci-
ety in question. Management of risks is a political, social, and economic issue. Scientists
acting as scientists have a role in this phase, but it is limited to ensuring that the biological
meaning of the risk is understood throughout the process.)
27Currentiy there are computer programs which will aid in the assessment process, hence
facilitating calculation and comparison of data. Crump, On Improved Procedure for Low-Dose Car-
cinogenic Risk Assessment from Animal Data, 5 J. ENv. PATHOLOGY AND ToxicoLoGy 675 (1982) (set-
ting water quality criteria using Global 82 computer program).
21'Animal study costs vary but one commentator places the price approximately at $75,000 in
1975 for the testing of one chemical for carcinogensis with one animal species. Note, Implement-
ing the Anti Cancer Clauses of the Food, Drug and Cosmetic Act, 44 U. CH. L. REv. 817, 829 n. 62
(1977).
2m Supra note 231. e.g., "here is the FDA saying in one day all carcinogens are banned because
they are inherently unsafe, and the next day allowing them to be added to our food." People
also do not want to be that one in a millionth person to get cancer.
n'See CASARET, & DOULL, supra note 5, at 713 (e.g. risk of being struck by lightning = 10- 6,
killed in auto accident = 8 x 10-3 (1/8,000), etc. - using 1976 statistics).
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ted to man.m Because quantitative risk assessment involves two extrapola-
tions, interspecies as well as intraspecies, it may arouse even more skepti-
cism. 3 The use of animal models in predicting human risk has been unduly
criticized; in scientific reality there is often little difference systematically be-
tween the species.2 4 The basic biologic processes are the same, with usually
only subtle physiological, anatomical and biochemical differences. Routes of
exposure, biodistribution, and mechanism of action (tissue function) differ
only slightly from species to species.1 Metabolism and pharmacokinetics
are often different, but much has been learned as to interspecies variabil-
ity.216 While some concern is warranted, once these variables have been de-
termined and accounted for, accurate risk assessment is possible. Current
research focuses upon interspecies conversion factors for physiologic and
biochemical processes and developing dose equivalencies and evaluating
the extent to which predictions based on these conversions agree with ob-
served data. -
A third concern that must be considered is "risk additivity."2 Current
risk assessment models are based on a certainty of cancer using one com-
pound. A problem arises when more than one compound is present. Sum-
mary review of this problem would lead us to believe that the Delaney
Clause in its current form would preclude such a situation.29 This logic ap-
pears faulty when it is realized that all compounds carry with them some
carcinogenic risk: even if an agent is not a carcinogen per se it may influence
I
mRall, Difficulties in Extrapolating the Results of Toxicity Studies in Laboratory Animals to Man, 2
ENv. REsEARcH 360 (1969).
2Supra note 259 and accompanying text. Intraspecies extrapolation has been discussed pre-
viously and involves high dose to low dose predictions based on curve-fittings.
2
mSee CAsAETrr& DOULL, supra note 5, at 120.
tm Id.
2NHogan and Hoel, Extrapolation to Man, in: PRiNCIPLES AND ME-SODS OF TOxiCOLOGY 711
(1982).
2171d. See also Gillette, Application of Pharmacokinetic Principles in the Extrapolation of Animal Data
to Humans, 9 CUNICAL ToXICOLoGY 709 (1976).
Also of current interest is predictions of dose based on body surface area rather than body-
weight. See Freireich, Gehan, and Rail, Quantitative Comparison of Toxicity of Anti-cancer Agents in
Mouse, Rat, Dog, Monkey and Man, 50 CANcER CHEMOTHERAPY REPORTS 219 (1966). (mg/kg versus
mg/m2 body surface extrapolation).
m
2 See generally Principles, supra note 5, at 10,394 (multiple agent exposure).
ITheoreticaly Delaney bans all carcinogens, with certain exceptions, in food. It is these
exceptions however, which may cause a problem. Some of those not regulated may create more
of a cancer risk than those which are. Supra notes 52 and accompanying test (exceptions to Dela-
ney).
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the carcinogenic potential of another compound.' The problem is complex,
especially when the simple adding up of risks most often leads to an inaccu-
rate finding of overall risk. Perhaps the ultimate method of evaluation will
hinge upon comparisons of risks and biological activities of the compounds
purported to be interacting and adjustments made to the margin of safety
used in each. This problem still should not preclude the use of risk assess-
ment as an alternative to the Delaney Clause because it is prevalent in both
situations.
As a final consideration it is imperative that pharmacological and pharma-
cokinetic studies are performed on all compounds, whether under Delaney
or otherwise. The administration of compounds in multiples of actual physi-
ological concentration leads to determinations that are inherently incorrect.
(e.g. either an under-estimation or over-estimation of risk) If for instance the
compound saturates a toxification pathway (i.e., after a certain dose the in-
crease in incidence of tumors over controls levels off) it may appear that the
compound is non-carcinogenic after this dose.2 1 While adequately con-
ducted tests should expose such a situation, its presence in a study may de-
tract from the credibility it deserves. More important is the reverse situation
where saturation of a detoxification pathway occurs. Risk will be overesti-
mated because at these high concentrations it will appear that the com-
pound may have a safe (dose-responsive) level. 22 These toxification/
detoxification pathways may include metabolic pathways found in the soft
tissues, i.e., liver, lung and kidney; and DNA repair. ' 3
Conclusion
The regulation of carcinogenic substances is not a task to be taken lightly.
Analysis of pertinent biologic processes reveals that virtually all substances
are potential carcinogens. To differentiate hazardous chemicals that pose
significant human risk, quantitative risk assessment promises to supplant
2ffrhis is probably best illustrated by the finding that ingestion of alcohol increases the car-
cinogenicity of benzo(A)pyrene in animals (smoking and drinking alcohol risk). CASARETr &
DOULL, supra note 5, at 116.
2'9The compound's activity would be similar to the maximal response as seen at the top of the
dose response curve. Supra note 192 (Figure 1).
mid. (If analyzed at a lower dose, a dose-response relation as to cancer induction could re-
sult).
'Supra note 200 and accompanying text (metabolism).
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the Delaney Clause and provide a more rational basis for regulating carcino-
gens. The Delaney Clause has generated considerable controversy since the
early 1950's. While banning carcinogenic food additives, food colors, and
animal drugs the FDA has seldom employed it. When it has, inconsistent
and questionable applications have resulted.
At this point in time it must be conceded that the quantitative risk assess-
ment approach is not perfect, but even in current form it surpasses the cur-
rent FDA cancer policy. This is due to continuous adherence to the biological
processes with which cancer is associated, and the appropriate use of scien-
tific judgment.
Perhaps the most pressing problem besides the adoption of the appropri-
ate procedures is uniformity of policy. Review of the overall cancer process
reveals that there is no difference between exposures to carcinogens in foods
or from the environment.21 While there is some interaction in the testing of
pesticide and animal drug residues between federal agencies,2 the regula-
tion of carcinogens has evolved differently and varies widely.2 6
Clearly a more uniform approach is required. Adoption by the FDA of
quantitative risk assessment procedures would be a step in that direction.
Furthermore, international recognition of the FDA's Good Laboratory Prac-
tices and Redbook" promise that food standards could be of world wide di-
mension. It can only be from rational and intelligent decision-making, as
well as national and international cooperation, that carcinogenic hazards
will be reduced.
2N4Supra note 213 (routes of exposure).
221 U.S.C. § 346a (1970) (the U.S.D.A. sets pesticide tolerances for FDA).
1There is a tremendous need for uniformity not only between the agencies but within
them. The FDA, for example regulates additives, "added" substances and natural constitutents
by different means. If this risk assessment proposed is employed for toxicity as well as carcino-
genicity testing the system would be much more simplified. The interagency uniformity (or lack
thereof) is even more profound. See Principles, supra note 5, at 10,428-10,432.
2
wSee Redbook, supra note 181.
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